The effects of polychlorinated biphenyls exposure on non-alcoholic fatty liver disease: role of aryl hydrocarbon receptor.

Hongxue Shi

University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd

Part of the Environmental Public Health Commons, Nutritional and Metabolic Diseases Commons, Pharmacology Commons, and the Toxicology Commons

Recommended Citation

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.
THE EFFECTS OF POLYCHLORINATED BIPHENYLS EXPOSURE ON NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF ARYL HYDROCARBON RECEPTOR

By

Hongxue Shi
M.S. Wenzhou Medical University, 2013

A Dissertation
Submitted to the Faculty of the
School of Medicine of the University of Louisville
for the Degree of

Doctor of Philosophy in Pharmacology and Toxicology

Department of Pharmacology and Toxicology
University of Louisville
Louisville, KY

May 2018
THE EFFECTS OF POLYCHLORINATED BIPHENYLS EXPOSURE ON NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF ARYL HYDROCARBON RECEPTOR

By

Hongxue Shi
M.S. Wenzhou Medical University, 2013

Dissertation Approved on

April 19, 2018

By the following Dissertation Committee

Matthew C. Cave, M.D., (Mentor)

Juliane I. Beier, Ph.D.

Wenke Feng, Ph.D.

Russell A. Prough, Ph.D.

J. Christopher States, Ph.D.
ACKNOWLEDGEMENTS

First, I would like to appreciate my mentor, Dr. Cave, for his guidance and support in the entire periods of research, as well as, his love to teach me how to balance the family and the work. I also would like to thank my dissertation committee, Dr. Beier and Dr. States, for their expertise in environmental pollutants exposure-induced liver injury and disease, Dr. Feng for his expertise in fibroblast growth factor 21 in fatty liver disease, and Dr. Prough, for his expertise in liver enzymes for drugs and chemicals metabolism, as well as, for his experience in scientific writing and communication skills.

I am also grateful to present and former members in Lab, including Dr. Falkner for his knowledge to help me to solve the problems, Dr. Clair for her assistance in teaching me how to isolate and culture primary mouse hepatocytes, and Mr. Hardesty and Mr. Jin for their hands in animal studies. Also, many thanks to Dr. Arteel Lab for facilities for tissue embedding and microtome, Dr. Feng Lab for jars for pathohistological analysis, and UofL Alcohol Research Center, for using other facilities.

I appreciate Dr. Hein and Dr. Cai in our department and Dr. Li and Dr. Xiao in Wenzhou Medical University, for their efforts to build the partnership between Department of Pharmacology & Toxicology and Wenzhou Medical University, providing me an opportunity to study here. I am also grateful to the present and former faculty and staff in our department for their help in doing research and in daily life.
Finally, I would like to thank my wife, Mrs. Xiao, and my daughter, Lola, for their love, support and encouraging in my life. Thanks to my parents and parents-in-law for their selfless love and support.
ABSTRACT

THE EFFECTS OF POLYCHLORINATED BIPHENYLS EXPOSURE ON NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF ARYL HYDROCARBON RECEPTOR

Hongxue Shi

April 19, 2018

Polychlorinated biphenyls (PCBs) are detectable in serum of 100% of adults in US, and has been associated with fatty liver disease in epidemiological studies. PCBs are classified as either dioxin-like (DL) or non-dioxin-like (NDL) PCB based on their ability to activate the aryl hydrocarbon receptor (AhR). We used exposures that reflect human bioaccumulation patterns, which resembles Aroclor 1260 with a low level of the DL-PCB, PCB 126. Our aim was to determine if this exposure will activate the human and mouse AhR and examine if receptor activation influences these steatotic responses due to PCB exposures.

DL-PCBs exposure-induced AhR activation in luciferase assays and induction of AhR target gene expression demonstrated that the Mouse AhR was much more sensitive than human AhR to activation by DL-PCBs. Our PCB mixture reflected this by activating the mouse AhR, but not human AhR in vivo. The ability of PCBs to activate the AhR would be predicted to be WHO toxicity equivalency = rat > mouse >> human.
Mice were exposed to either PCB 126 (20 μg/kg), Aroclor 1260 (20 mg/kg) or both, for 2 weeks. PCB 126 or Aroclor 1260/PCB 126 significantly activated AhR, but only PCB 126 exposure alone induced mild hepatic steatosis. AhR activation suppressed the induction of CAR and PXR targets. More complex patterns of attenuation were observed with genes involved in lipid metabolism.

PCB exposures require a hypercaloric diet to transition steatosis to steatohepatitis in murine models. Mice were fed high fat diet and received the same treatments as the 2-week study for 12 weeks. Our PCBs mixture exposure did not induce wasting syndrome, and failed to exacerbate steatosis. In addition, PCB 126 exposure activated AhR. Aroclor 1260 exposure drove hepatic steatosis to steatohepatitis. Either PCB 126 or the Aroclor 1260/PCB 126 mixture protected against high fat diet induced liver injury and liver fibrosis. All PCB exposures affected hepatic lipid metabolism.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENT</td>
<td>iii</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>v</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>xii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>xiii</td>
</tr>
<tr>
<td><strong>CHAPTER I</strong></td>
<td></td>
</tr>
<tr>
<td>GENERAL INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>Non-alcoholic fatty liver disease</td>
<td>1</td>
</tr>
<tr>
<td>Polychlorinated biphenyls</td>
<td>5</td>
</tr>
<tr>
<td>Xenobiotic receptors</td>
<td>11</td>
</tr>
<tr>
<td>Aims and significance of current study</td>
<td>15</td>
</tr>
<tr>
<td><strong>CHAPTER II</strong></td>
<td></td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>18</td>
</tr>
<tr>
<td>MATERIALS AND METHODS</td>
<td>20</td>
</tr>
<tr>
<td>Reagents</td>
<td>20</td>
</tr>
<tr>
<td>Animal exposures</td>
<td>20</td>
</tr>
<tr>
<td>Histological staining</td>
<td>21</td>
</tr>
<tr>
<td>Real-time PCR</td>
<td>21</td>
</tr>
</tbody>
</table>
Measurement of hepatic lipid ................................................................. 22
Measurement of plasma lipid and cytokine ........................................ 22
Statistical analysis .................................................................................. 23
RESULTS ........................................................................................................... 24
Effects of PCB exposures on body weight and composition ....................... 24
Effects of PCB exposures on hepatic expression of AhR, CAR, PXR, and their target genes ................................................................. 26
Effects of PCB exposures on hepatic lipids ................................................ 29
Effects of PCB exposures on plasma lipids ............................................... 32
Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression .......... 33
Effects of PCB exposures on other genes of hepatic lipid metabolism .............. 35
Effects of PCB exposures on hepatokine expression ................................... 38
Effects of PCB exposures on pancreas structure ........................................ 40
Effect of PCB exposures on pancreatic function ...................................... 42
Effects of PCB exposures on hepatic gluconeogenic genes expression ............ 44
DISCUSSION ..................................................................................................... 45
CHAPTER III
INTRODUCTION ............................................................................................ 52
MATERIALS AND METHODS ........................................................................ 54
Reagents ........................................................................................................ 54
Animal exposures ......................................................................................... 54
Histological staining .................................................................................... 55
Real-time PCR ............................................................................................... 55
Cell treatment and RT-PCR

Statistical analysis

RESULTS

Concentration-response curves for the luciferase assay activated by TCDD

Concentration-response curves for the luciferase assay and Cyp1a1 expression activated by non-ortho PCB 126

Concentration-response curves for the luciferase assay activated by mono-ortho PCB 114

Concentration-response curves for the luciferase assay activated by non-ortho PCB 81

DL/NDL-PCBs mixture activates mouse AhR

CHAPTER V

CONCLUSIONS

Overall goals and specific aims

Major findings of current dissertation

Strengths and limitations of this dissertation

REFERENCES

Summary

107
106
104
105

112
99
96
95
93
92
90
88
89
96
92
88
89
88
88
ABBREVIATIONS ......................................................................................... 123
CURRICULUM VITAE .................................................................................. 126
LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>The AhR EC₅₀ values in human and mouse</td>
<td>103</td>
</tr>
<tr>
<td>4.2</td>
<td>Relative Effect Potency Values (REPs)</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>Supplemental Table 1 Effects of PCB exposures on liver, pancreas and blood</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in control synthetic diet fed mice for 2 weeks</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>Supplemental Table 2 Effects of PCB exposures on liver and blood in high</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fat diet fed mice for 12 weeks</td>
<td>111</td>
</tr>
</tbody>
</table>
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>The homeostasis of liver lipid metabolism</td>
<td>2</td>
</tr>
<tr>
<td>1.2</td>
<td>The global estimated prevalence of NAFLD and PNPLA3 rs738409 genotype</td>
<td>4</td>
</tr>
<tr>
<td>1.3</td>
<td>Chemical structure of PCBs</td>
<td>6</td>
</tr>
<tr>
<td>1.4</td>
<td>Chemical structure of dioxin-like PCB congeners</td>
<td>8</td>
</tr>
<tr>
<td>1.5</td>
<td>Relative PCB composition in human adipose tissue and Aroclor 1260</td>
<td>10</td>
</tr>
<tr>
<td>1.6</td>
<td>Scheme of AhR activation by agonist binding</td>
<td>13</td>
</tr>
<tr>
<td>2.1</td>
<td>Effects of PCB exposures on liver and fat weight</td>
<td>25</td>
</tr>
<tr>
<td>2.2</td>
<td>Effects of PCB exposures on levels of hepatic AhR, CAR, PXR, and their target genes expression</td>
<td>28</td>
</tr>
<tr>
<td>2.3</td>
<td>Effects of PCB exposures on hepatic lipids</td>
<td>30</td>
</tr>
<tr>
<td>2.4</td>
<td>Effects of PCB exposures on plasma lipid levels</td>
<td>32</td>
</tr>
<tr>
<td>2.5</td>
<td>Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression</td>
<td>34</td>
</tr>
<tr>
<td>2.6</td>
<td>Effects of PCB exposures on genes expression of hepatic lipid metabolism</td>
<td>37</td>
</tr>
<tr>
<td>2.7</td>
<td>Effects of PCB exposures on hepatokines expression</td>
<td>39</td>
</tr>
<tr>
<td>2.8</td>
<td>Effects of PCB exposures on pancreatic structure</td>
<td>40</td>
</tr>
<tr>
<td>2.9</td>
<td>Effects of PCB exposures on pancreatic gene expression</td>
<td>43</td>
</tr>
</tbody>
</table>
Figure 2.10 Effects of PCB on gluconeogenic genes expression ......................... 44
Figure 3.1 Effects of PCB exposures on body weight and composition after 12 weeks exposure ................................................................. 58
Figure 3.2 Effects of PCB exposures on AhR, CAR and their target genes ............. 60
Figure 3.3 Effects of PCB exposures on hepatic steatosis ................................ 62
Figure 3.4 Effects of PCB exposures on liver injury ........................................ 64
Figure 3.5 Effects of PCB exposures on hepatic inflammatory response .......... 66
Figure 3.6 Effects of PCB exposures on plasma lipids and adipokines ............... 69
Figure 3.7 Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression ............................................................... 70
Figure 3.8 Effects of PCB exposures on other genes of hepatic lipid metabolism .... 72
Figure 3.9 Effects of PCB exposures on glucose metabolism .............................. 74
Figure 3.10 Effects of PCB exposures on hepatic fibrosis .................................. 76
Figure 4.1 Concentration-response curves for the luciferase assay activated by TCDD...... ................................................................................................................. 89
Figure 4.2 Concentration-response curves for the luciferase assay and Cyp1a1 expression activated by non-ortho PCB 126 ......................................................... 91
Figure 4.3 Concentration-response curves for the luciferase assay activated by non-ortho PCB 169 ................................................................................................. 92
Figure 4.4 Concentration-response curves for the luciferase assay activated by non-ortho PCB 81 ................................................................................................. 93
Figure 4.5 Concentration-response curves for the luciferase assay activated by mono-ortho PCB 114 ................................................................................................. 94
Figure 4.6 Concentration-response curves for the luciferase assay activated by non-ortho PCB 77 ................................................................. 95
Figure 4.7 DL/NDL-PCBs mixture activates mouse AhR ........................................... 98
Figure 5.1 PCB exposures affected homeostasis of liver lipid metabolism ............ 109
CHAPTER I
GENERAL INTRODUCTION

1. Non-alcoholic fatty liver disease

High calorie intake or a Western diet contributes to non-alcoholic fatty liver disease (NAFLD), which is manifested by excessive lipid accumulation in liver, termed hepatic steatosis. NAFLD encompasses a spectrum of fatty liver diseases, ranging from hepatic steatosis to hepatic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC) (1). Inflammatory cell infiltration drives hepatic steatosis to progress to NASH, which is characterized by hepatic injury, inflammation, oxidative stress and fibrosis. Hepatic steatosis and steatohepatitis can be reversed after timely intervention. If not, steatohepatitis can progress to advanced cirrhosis, which is associated with a high risk of HCC (2).

Liver is one of the important organs in regulation of glucose and lipid metabolism, and the dysfunction of glucose and lipid metabolism are fundamental in development and progression of NAFLD. The homeostasis of lipid metabolism includes lipid input and output in liver (Figure 1.1). On the input side, lipids can be taken up via the blood stream in the form of chylomicrons (CM) from dietary fat ingestion and free fatty acids derived mainly from lipolysis. Lipids may be synthesized (de novo) from carbohydrates or other precursors. The key proteins involved in influx of fatty acid in liver include fatty acid transport proteins (FATPs), plasma membrane fatty acid binding protein (FABP) and fatty acid translocase (CD36/FAT), which are associated with hepatic steatosis (3-5). The key
enzymes involved in *de novo* lipogenesis are ATP-citrate lyase (Acly), acetyl-CoA carboxylase (ACC) and fatty acid synthase (Fasn) (6). Moreover, the transcription factors, such as liver X receptor (LXR), sterol regulatory element-binding protein-1c (SREBP-1c), and carbohydrate response element binding protein (ChREBP) also control *de novo* lipogenesis (7, 8). Free fatty acids are mainly used to synthesize triglycerides and are stored in hepatocytes. On the output side, lipids can be secreted into blood in lipoprotein form, such as very-low-density-lipoprotein (VLDL) by interaction with apolipoproteinB-100 (ApoB-100) (8), and be utilized in mitochondria (fatty acid oxidation) as an energy source to produce ATP (9). In the normal physiological status, the liver total lipids input equals the total lipids output. However, once the total lipids input rate exceeds output rate, excessive lipids would be ectopic deposited, resulting in hepatic steatosis. Therefore, the factors that disturb the balance of lipid metabolism will induce NAFLD.

![Figure 1.1](image.png)

Figure 1.1 The homeostasis of liver lipid metabolism. Figure adapted from Jonathan C. Cohen *et al.*, *Science*, 2011; 332:6037
The prevalence of NAFLD parallels the incidence of obesity and type 2 diabetes (T2DM). With the increasing incidence of obesity and T2DM, NAFLD is the most prevalent liver disease with a global prevalence estimate of 24 %, with the highest rates of NAFLD in South America (31 %) and the Middle East (32 %), followed by Asia (27 %), the USA (24%) and Europe (23 %), and lowest in Africa (14 %) (10, 11). The prevalence of NAFLD across geographical locales is shown in Figure 1.2 based on community surveys (11). Not all subjects with obesity develop NAFLD; and not all subjects with steatosis develop progressive liver disease. Seventy to eighty percent of obese and diabetic individuals develop NAFLD, 5-10 % subject with steatosis develop NASH, and 30 % of patients with NASH develop cirrhosis. Among patients diagnosed with cirrhosis, only 1-2 % of patients progress to HCC within 10 years of developing cirrhosis (12). The pathogenesis of NAFLD development, and progression to advanced fatty liver disease is not completely understood. Generally, the interaction of lifestyle (13), nutrients (14) and genetics (15) affect the pathogenesis of NAFLD/NASH. The potential molecular mechanisms include insulin resistance, lipotoxicity, mitochondrial oxidative stress, ER stress, disrupted adipokines, inflammatory cytokines, autophagy, and changes in gut microbiome (16-18). Several susceptibility genes for NAFLD development have been identified, such as patatin-like phospholipase domain-containing-3 (PNPLA3). The PNPLA3 (rs738409) polymorphism genotype distribution correlates with worldwide prevalence of NAFLD (Figure 1.2) (11, 19, 20).
NAFLD is associated with abnormal level of blood lipids that increase mortality from liver and cardiovascular disease. Indeed, hypertriglyceridemia is the metabolic comorbidity most frequently associated with NAFLD. For patients with end stage liver disease, and cirrhosis, liver transplantation is the major strategy to rescue them. Thus, NAFLD is a heavy burden on public health globally. In the USA, it is estimated annual direct medical costs for NAFLD are about $103 billion (21). To date, there are no FDA-approved drugs for NAFLD/NASH treatment, and lifestyle improvements, such as body weight loss and physical exercise, are the only ways to improve NAFLD/NASH (22). However, experimental therapies involve targeting hepatic fat accumulation, anti-oxidants, anti-inflammation, anti-apoptosis, gut microbiome and anti-fibrotic (23, 24). Among these
developed chemicals, dual peroxisome proliferator-activator receptor α/δ agonist (elafibranor) (25, 26), farnesoid X receptor agonist (obeticholic acid) (27, 28), apoptosis signaling kinase 1 (ASK1) inhibitor (29, 30), and cysteine–cysteine motif chemokine receptor-2/5 antagonist (cenicrivivroc) (31, 32), are being evaluated in phase III trial for NAFLD/NASH.

The “two-hit” hypothesis of NAFLD/NASH has been proposed (33), but this view has been challenged by “multiple parallel hits” hypothesis based on recent new findings (34). In the “two-hit” hypothesis, fat accumulation serves as the first hit, and increases susceptibility to subsequent second hits, which are responsible for liver injury, inflammatory cell infiltration and hepatic fibrosis. Occupational and environmental chemicals are another category of second hit. The terms toxicant-associated fatty liver disease (TAFLD) and/or toxicant-associated steatohepatitis (TASH) have been proposed to describe this condition (35). The TASH was firstly described in non-obese vinyl chloride (VC) workers, which is characterized by the presence of necrotic cell death, as indicated by elevated total cytokeratin 18, elevated proinflammatory cytokines, impaired insulin sensitivity and antioxidant defenses, but with normal serum transaminases levels. Selected pollutants associated with TAFLD/TASH in human and animal studies have been reviewed (36, 37). Since the similar histopathology exists among NAFLD/NASH and TAFLD/TASH, the distinction between them will not be made in the following text.

2. Polychlorinated biphenyls

Polychlorinated biphenyls (PCBs) are thermodynamically stable polyhalogenated aromatic hydrocarbons consisting of up to ten chlorine substituents attached to biphenyl rings (Figure 1.3). There are 209 different congeners, defined by the number and position
of chlorines attached to the biphenyl rings. Due to their thermodynamic stability and excellent electrical insulation and heat transfer properties, PCBs were widely used as insulating fluids in electrical transformers and capacitors. A total of 1.3 million tons of PCB mixtures were produced for a variety of commercial applications before PCBs were banned. PCB production was banned by the United States Congress in the later 1970’s and globally by the Stockholm Convention in 2001 (38).

Figure 1.3 Chemical structure of PCBs. PCBs have the basic chemical formula \((C_{12}H_{10-n}Cl_n)\), where \(n\) means the number of chlorine atoms, and number means the positions where a chlorine atom is attached to biphenyl rings.

Although PCBs production was banned for more than 30 years, PCBs still exist in the environment due to their higher thermostability, and resistant to degradation by the microbes, thus, PCBs belong to a category of “persistent organic pollutants” (POPs), and are widely dispersed in the global ecosystem, including water, soil, air, aquatic wildlife and mammals (39, 40). Highly chlorinated PCBs have bioaccumulated and are detected in human adipose tissues, liver, serum, and milk due to low metabolic degradation rate (41-43). Currently, inadvertent PCB production still occurs (44) and PCBs exposure occur
mainly through inhalation of contaminated indoor air (45) and contaminated food consumption (46).

The chlorination pattern of the PCBs is important for the toxicity of these congeners. PCB congeners have been subclassified into two major categories: coplanar and non-coplanar PCBs. Coplanar PCB congeners have none or only one chlorine atom attach to the ortho-position of biphenyl rings, known as non-ortho and mono-ortho PCBs, respectively. There are total 12 coplanar PCBs. Non-ortho PCBs include PCB 77, PCB 81, PCB 126, and PCB 169, and the rest of them are mono-ortho PCBs, such as PCB 114 and PCB 189, etc (Figure 1.4). Coplanar PCBs exhibit dioxin-like toxicity, and are also known as dioxin-like (DL) PCBs. Non-coplanar PCB congeners have two or more chlorine atoms at the ortho-position of biphenyl rings, and do not resulted in dioxin-like properties, thus, they are known as non-dioxin-like (NDL) PCBs.

The DL-PCB congeners interact with aryl hydrocarbon receptor (AhR), which may mediate their toxic effects. Among 12 DL-PCB congeners, PCB 126 exhibits the highest AhR binding affinity, and is the potent congener of DL-PCBs. Therefore, PCB 126 was selected for the proposed studies. Animal studies have shown that the toxic effects of PCB 126 include developmental toxicity (47), hepatic toxicity (48), reproductive toxicity (49), and neurological toxicity (50). The unfavorable effects of PCB 126 may be also mediated by interaction with other receptors, such as estrogen receptor (ER) (51). On the other hand, the toxicologic mode of action of NDL-PCBs, has been attributed to interactions with a variety of other cellular receptors, including pregnane X receptor (PXR) and constitutive androstane receptor (CAR) (52), as well as, ER, androgen receptor, and thyroid receptor (53). However, the DL-PCBs may also interact with these receptors (52, 53).
Figure 1.4 Chemical structure of DL-PCB congeners. The DL-PCBs in left column are non-ortho PCBs, and the rest of them are mono-ortho PCBs. Figure adapted from website:
https://en.wikipedia.org/wiki/Polychlorinated_biphenyl

The liver is the major organ for PCB metabolism via phase I (cytochrome P450 enzymes) and phase II (conjugation pathways) pathways to convert them to water soluble metabolites, and remove them from body. The detailed metabolic pathways of PCBs bio-transformation are well summarized and reviewed (54). The rate and extent of PCB metabolism depends on the numbers and position of chlorines in the biphenyl rings. Generally, the lower the number of chlorines on the biphenyl rings, the faster the metabolism. Therefore, highly chlorinated PCBs tend to be bio-accumulated and detected
in human fat tissues or in plasma due to their lipophilic properties (55). In fact, the median concentration of the sum of 35 PCB congeners (ΣPCBs) was 528 ng/g lipid in participants of the Anniston Community Health Survey (ACHS) (55), and ACHS participants have serum concentrations of ΣPCBs two to three times higher than those in comparable age and race groups from National Health and Nutrition Examination Survey (NHANES) 2003–2004 sample of the general United States population (56).

Commercial PCBs were made and used in mixtures rather than individual congeners. In the United States, commercial PCB mixtures were produced by the Monsanto Company and marketed under the trade names Aroclor. Manufacturing plants included Anniston, Alabama. There are different types of Aroclor mixtures and each of them has a distinguishing suffix number that indicates the degree of chlorination. The first two numbers usually mean the total number of carbon atoms in biphenyl rings and the last two digits refer to the percentage of chlorines by mass in the mixture. Commercial PCB mixtures were also made globally, and marketed under different trade names. ACHS study demonstrated that higher incidences of hypertension, obesity, diabetes and liver disease was positively correlated to PCBs load in residents (57, 58).

Aroclor 1260, one of the commercial PCB mixtures in North America, contains sixty percent chlorine atoms by mass. The PCB congeners of Aroclor 1260 usually are highly chlorinated congeners with more than 5 chlorine substituents. As lowly chlorinated PCB congeners are easily metabolized and eliminated, only highly chlorinated PCB congeners are resistant to metabolism, and have bio-accumulated in humans. Our previous study demonstrated that the PCB profiles in Aroclor 1260 best mimic the PCBs present in human adipose tissue (52) (Figure 1.5). However, Aroclor 1260 contains lower amounts of DL-
PCB congeners. A 20 mg/kg exposure of Aroclor 1260 did not activate AhR in mice (52, 59). The less chlorinated PCB mixtures were also made by Monsanto Company with tradenames Aroclor 1254, Aroclor 1242, and Aroclor 1248, etc, later.

![Figure 1.5 Relative PCB composition in human adipose tissue and Aroclor 1260.](image)

Figure 1.5 Relative PCB composition in human adipose tissue and Aroclor 1260. Figure adapted from Wahlang, et al., Toxicol Sci, 2014,140 (2): 283-297.

Two major human PCB exposure events occurred in Japan (known as “Yusho”) in 1968 (60) and in Taiwan (known as “Yucheng”) in 1978 (61), both as results of contaminated rice oil consumption. In Yusho, maternal exposed women tend to give offspring with lower birth weight (62). Follow-up studies of the Yucheng events have demonstrated neurocognitive deficits in elderly women patients (63) and increased mortality from chronic liver disease and cirrhosis in men (64, 65). Moreover, multiple epidemiological studies have reported associations between PCB exposure and suspected steatohepatitis (42) and/or diabetes (57, 66) in NHANES and ACHS studies.
As liver is the major site of PCB metabolism, and the lower chlorinated metabolites could adduct to DNA, proteins and lipids, and associate with activation of various hepatic receptors; thus, liver is the major target organ for the toxic effects of PCBs exposure. The nutrient-PCB interaction also affects PCB toxicity in liver. For example, DL-PCBs interact with AhR, and induce NAFLD in normal diet, while NDL-PCBs mixture interact with nuclear receptors, and exacerbate high fat diet-induced injury, leading to NASH. Therefore, PCBs have also been classified as endocrine and metabolism disrupting chemicals (EDCs/MDCs). EDCs interfere with any aspect of hormone action, resulting in endocrine dysfunction; while MDCs promote metabolic changes, resulting in metabolic disease (66).

3. Xenobiotic receptors

The functions of xenobiotic receptors are not only related to chemical detoxification, but also contribute to glucose and lipid metabolism, which are associated with metabolic disease, including NAFLD/NASH. In the current dissertation, the xenobiotic receptors of aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and pregnane x receptor (PXR) will be discussed.

The AhR is a ligand-binding activated transcription factor that belongs to the Per-Arnt-Sim family. The molecular mechanisms of AhR activation have previously been reviewed (67) (Figure 1.6). Unliganded AhR resides in cytoplasm of cells, forming a protein complex with a heat shock protein 90 (HSP90) dimer and the co-chaperone protein X-associated protein 2 (XAP2), collectively they retard AhR translocation to nucleus. Upon binding an agonist, the AhR complex translocates to the nucleus and AhR nuclear translocator (ARNT) mediates HSP90 displacement, leading to AhR-ARNT heterodimer formation. This dimer is capable of binding to a dioxin-responsive element (DRE), thereby
regulating the transcription of many genes, such as the cytochrome P4501A (CYP1A) family. Cyp1a1 and Cyp1a2, are the major members of Cyp1a family that metabolize the pro-carcinogenic chemicals to their carcinogenic form, which react with DNA to form mutagenic adducts, resulting in carcinogenesis. The high-affinity binding agonists for AhR are often xenobiotics, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2-benzo[a]pyrene (BA) and DL-PCBs. Moreover, low-affinity binding agonists for AhR have been discovered in diet (flavonoids and indoles), endogenously as bilirubin and tryptophan metabolites, and as products of the microflora (67, 68). On the other hand, ligand-independent indirect activation of AhR has been reported, such as that seen with omeprazole (69).

Associated with regulation of physiological functions, such as innate and adaptive immune responses (68), AhR activation also is involved in the processes of glucose and lipid metabolism. Pharmacologic activation of AhR (70) or constitutively activated AhR (71) induces hepatic steatosis via upregulation of fatty acid transport genes, such as CD36/FAT. Alteration of hepatic fatty acid composition (72) and decreased fatty acid oxidation (73) contribute to AhR ligand-induced liver toxicity and steatosis. On the contrary, AhR deficiency protects against high fat diet-induced obesity, improves insulin sensitivity, and attenuates hepatic steatosis (74, 75). Interestingly, liver-specific AhR knockout mice are prone to HFD-induced hepatic steatosis, inflammation and injury (76), suggesting AhR activation protects against fatty liver disease. Moreover, a disassociation of hepatic steatosis and insulin resistance has been found in constitutively activated AhR mice (77) by inducing a novel AhR target gene, fibroblast growth factor 21 (FGF21) (78). Moreover, TCDD or PCB 126 exposure-induced AhR activation suppresses hepatic
gluconeogenesis by inhibition of gluconeogenic gene expression, such as phosphoenolpyruvate carboxykinase (Pck1) (73, 79, 80).

Figure 1.6 Scheme of AhR activation by agonist binding. Figure are adapted from Murray et al., Nat Rev Cancer, 2015, 14 (12): 801-814.

PXR (nuclear receptor subfamily 1, group I, member 2, NR1I2) and CAR (nuclear receptor subfamily 1, group I, member 3, NR1I3) are members of the orphan nuclear receptor subclass. The major functions of these receptors are regulating transformation and elimination of chemicals in liver by regulation of phase I and phase II drug metabolizing enzymes and drug transporters (81). The direct and indirect molecular mechanisms of CAR and PXR activation have been reviewed (82). A variety of structurally related PXR and CAR ligands has been reported, including drugs, environmental pollutants, and endobiotics. Moreover, specific ligands diversity and species diversity are well known. For example,
the CAR ligands for human and mouse are 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehydeO-(3,4-dichlorobenzyl)oxime (CITCO) and 1,4-bis[2-(3,5-dichloropyridyl-oxy)]benzene (TCPOBOP), respectively. Activation of PXR induces expression of target genes of the Cyp3a family, including Cyp3a11 in mice and Cyp3a4 in human, while CAR target genes of the Cyp2b family, such as Cyp2b10 in mice and Cyp2b6 in human, are induced upon activation. PXR and CAR are sister xenobiotic receptors as they regulate many overlapping genes involved in chemical and drug detoxification and transportation.

Similar to AhR, PXR and CAR activities also are involved in metabolic disease by modulating glucose, fatty acid, and lipid metabolism directly or indirectly (81, 83, 84). CAR activation increases insulin sensitivity, improves type 2 diabetes and fatty liver disease (85, 86). Moreover, TCPOBOP treatment attenuates methionine choline-deficient (MCD) diet-induced NASH (87). The role of PXR activation in obesity is controversial, as ligand-induced PXR activation protects against high fat diet-induced obesity (88), while PXR ablation alleviates high fat diet-induced or genetic obesity, and improves insulin sensitivity (89). Activation of either PXR or CAR suppresses hepatic gluconeogenic gene expression by inhibition of transcriptional factors such as forkhead box protein O1 (FoxO1), hepatocyte nuclear factor 4 alpha (HNF4α), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) (90, 91). Furthermore, PXR activation suppresses inflammation and is a promising target for inflammatory diseases (92).

The detoxification of PCBs is associated with nuclear receptor CAR and PXR activation, and in turn, CAR and PXR activation affect PCBs exposure-induced metabolic disorders. Our previously published data suggest Aroclor1260, a NDL-PCB congeners mixture, activates human PXR and CAR3 variant, and is a mixed agonist/antagonist for
the human CAR2 variant based on cell culture model (52). In vivo, Aroclor 1260 treatments activate CAR and PXR, as evidenced by induced expression of their target genes, Cyp2b10 and Cyp3a11 at low doses, Aroclor 1260-induced expression of AhR target gene Cyp1a2 requires much higher doses due to the low amounts of DL-PCBs (59). Moreover, Aroclor 1260 treatments promote hepatic steatosis progression to steatohepatitis only at low dose, but not at high dose, under high fat diet conditions. PCB congeners apparently do not directly bind with the CAR, and the potential indirect mechanism of activation of CAR by Aroclor 1260 exposure may be EGFR signaling inhibition (93, 94), this similar to the molecular mechanisms that was shown by the CAR indirect activator, phenobarbital (95).

4. Aims and significance of current study

Although animal exposure models have typically investigated the toxic effects of only single PCB congeners or NDL-PCBs mixture treatments, humans are simultaneously exposed to mixtures of DL- and NDL-PCB congeners. Because the DL- and NDL-PCBs have different toxicological mechanisms of action, exposures to both types of PCBs might be synergistic or not. Therefore, the aims of the current dissertation are to investigate and compare DL-PCB congener (PCB 126), NDL-PCBs mixture (Aroclor 1260), and DL/NDL-PCBs mixture (Aroclor 1260 plus PCB 126) exposure related NAFLD/NASH and metabolic dysfunction. The potential role of AhR in PCB mixtures exposure-induced NAFLD/NASH will also be investigated.

As aforementioned, Aroclor 1260 best mimics PCBs that are seen in human adipose tissue (52), and Aroclor 1260 exposure is considered to be a ‘second hit’ in the conversion of diet-induced hepatic steatosis to the more advanced steatohepatitis. However, Aroclor 1260 (20 mg/kg) did not induce hepatic expression of prototypical AhR target genes (52,
59), because it did not contain a significant amount of DL-PCBs, such as PCB 126. To best mimic the DL/NDL-PCBs bioaccumulation pattern and the highest levels of exposure seen in humans (52), we added a small quantity of DL-PCB 126 which represents approximately 0.02% of human total PCBs exposure based on NHANES data. Because PCB 126 is not the only DL-PCB congener extant, and human exposures vary, the PCB 126 dose was increased to 0.1% (20 µg/kg).

The specific aims of my dissertation are shown as follows.

Specific Aim 1 will address whether DL-PCBs, NDL-PCBs, and DL/NDL-PCBs act differently on fatty liver disease. We will use male C57BL/6 mice on control synthetic diet to ascertain whether single treatment with Aroclor 1260, PCB 126, or Aroclor 1260/0.1% PCB 126 for 2 weeks activate AhR and downstream target genes, and lead to steatosis and liver injury (inflammatory markers, steatosis markers, and lipid metabolism markers). Next, male wild type C57BL/6 mice fed fat diet received the same PCB treatments for 12 weeks. The animals will be sacrificed and the liver mRNA levels of disease markers (receptors and their downstream targets, inflammatory markers, markers of fat metabolism), and pathological changes will be measured, to ascertain whether AhR is essential for PCBs-induced liver disease.

Specific Aim 2 will address whether human and murine AhR display the same concentration-dependence for ligand activation in response to PCBs. Initially, we will use cultured human (HepG2) and murine (Hepa1c1c7) hepatoma cells transfected with a XRE-Luc reporter to determine the relative affinity of the mixture Aroclor 1260, Aroclor 1254, selected DL-PCB congeners, including PCB 126, PCB 77, PCB 114, and PCB 81, and a mixture of DL/NDL-PCBs mixture (Aroclor 1260 plus 0.1% PCB 126, Ar1260/PCB 126).
This allows us to ascertain if the murine and human AhR are equally sensitive to PCB ligands or if the murine AhR binds ligands with higher affinity than the human receptor. We subsequently used murine and human primary hepatocytes to further test this hypothesis in an *in vitro* model. This aim is important for reverse translation studies utilizing mouse models of NAFLD.
CHAPTER II
ACUTE POLYCHLORINATED BIPHENYL TREATMENTS REGULATE HEPATIC METABOLISM AND PANCREATIC FUNCTION: IMPLICATION FOR NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES

1. Introduction

The commercially manufactured PCBs mixture that best mimics human PCB (by mass) bioaccumulation patterns in adipose tissue is Aroclor 1260, which is a NDL-PCBs mixture (52). Aroclor 1260 is considered a ‘second hit’ in the conversion of diet-induced hepatic steatosis, to the more advanced steatohepatitis. It also decreased pancreatic insulin production (59). However, low doses of Aroclor 1260 (20 mg/kg) did not induce hepatic expression of prototypical AhR target genes (52, 59), because it should not contain a significant amount of DL-PCBs, such as PCB 126, as indicated by high doses of Aroclor 1260 (200 mg/kg) required to observe AhR activation. Therefore, a high dose of PCB 126 was used to evaluate the toxic effects on fatty liver disease (48, 96, 97).

While humans are simultaneously exposed to mixtures of DL- and NDL-PCBs, animal exposure models have typically investigated the effects of only a single congener or NDL-PCBs mixture as mentioned before. Because the DL- and NDL-PCBs have different toxicological mechanisms of action, DL/NDL-PCBs mixture exposures to both types of PCBs might be synergistic. In PCB mixtures and especially among bioaccumulated PCBs, DL-PCBs are minor constituents. Using NHANES data, PCB 126 represents approximately 0.02% of the total PCB load in human serum (98).
The purpose of this subacute exposure study was to perform an integrated analysis of liver, pancreas, and serologic endpoints using exposures that better mimic high level human exposures to examine if the rodent AhR is activated and if mixtures of DL- and NDL-PCBs will behave like DL- or NDL-PCBs alone. My hypothesis is that at the highest human levels of exposure observed in literature, the rodent AhR will be activated, but that mixtures of DL- and NDL-PCBs will act differently. The mice were fed a control synthetic diet and exposed to: a low-dose of a DL-PCB congener (PCB 126, 20 µg/kg), an NDL-PCB mixture (Aroclor 1260, 20 mg/kg), an environmentally relevant mixture of low-dose PCB 126 (20 µg/kg) plus Aroclor 1260 (20 mg/kg); or vehicle. The possible impact of PCBs on novel mechanisms of endocrine and metabolic disruption [e.g., novel hepatokines (99) and genes regulating pancreatic islet cell identity and function (100)] will be investigated. This study could inform the direction of subsequent studies of combined exposures to PCB mixtures and hypercaloric diets in the metabolic syndrome.
2. Materials and Methods

Reagents

Aroclor 1260 and PCB 126 were purchased from AccuStandard, Inc., (New Haven, CT). RNA-STAT 60 were ordered from Amsbio., (Austin, TX) and QuantiTect Reverse Transcription Kit were obtained from Qiagen, (Valencia, CA). iTaq Universal probes Supermix was supplied by Biorad, (Hercules, CA). Taqman probes for real-time polymerase chain reaction (RT-PCR) and Infinity™ Triglycerides were obtained from Thermo Fisher Scientific, Inc., (Middletown, VA). Free fatty acids test kits were purchased from Roche Dignostics, (Indianapolis, IN). Lipid panel plus kits were obtained from Abaxis, (Union City, CA). The customized Milliplex® MAP Panel was obtained from Millipore Corp, (Billerica, MA). The other reagents were obtained from Sigma-Aldrich, (St. Louis, MO).

Animal exposures

The animal protocol used was approved by the University of Louisville Institutional Animal Care and Use Committee. Male C57BL/6j mice (10 weeks old) were obtained from The Jackson Laboratory (Bar Harbor, ME), and divided into 4 groups (n=10) based on the different exposures. All the mice were fed a control synthetic diet (20.0 %, 69.8 %, and 10.2 % of total calories come from protein, carbohydrate, and fat, TekLab TD06416). Mice were treated by one-time gavage with either Aroclor 1260 (20 mg/kg), PCB 126 (20 µg/kg), Aroclor 1260 (20 mg/kg) with 0.1 % PCB 126 (20 µg/kg) or vehicle control (corn oil) for 2 weeks. Mice were housed in a temperature- and light controlled-room (12 h light; 12 h dark) with food and water ad libitum. The animals were euthanized at the end of week 2 using ketamine/xylazine (100/20 mg/kg body weight, i.p.) and the blood, liver, pancreas,
and fat tissues were collected. Dual energy X-ray absorptiometry (DEXA) scanning (Lunar PIXImus densitometer, WI) was performed to analyze body fat composition prior to euthanasia.

**Histological staining**

The liver and pancreas tissues were fixed in 10% neutral buffered formalin for 72 hours and embedded in paraffin for routine histological examination. Hematoxylin–eosin (H&E) staining were performed to observe histopathological changes. Photomicrographic images were acquired using a high-resolution Olympus digital scanner on an Olympus digital camera (BX41).

**Real-time PCR**

The liver and pancreas tissues were homogenized and total RNA was extracted using RNA-STAT 60 according to the manufacture’s protocol. The purity and quantity of total RNA were assessed with Nanodrop spectrometer (ND-1000, Thermo Fisher Scientific, Wilmington, DE) using ND-1000 V3.8.1 software. cDNA was synthesized using the QuantiTect Reverse Transcription Kit according to the manufacture’s protocol. RT-PCR was performed on the CFX384 TM Real-Time System (BioRad, Hercules, CA) using iTaq Universal probes Supermix and Taqman probes. The probes sequence were as follows: mouse AhR (Mm00478932_m1); mouse CAR (Nr1i3) (Mm01283978_m1); mouse PXR (Nr1i2) (Mm01344139_m1); cytochrome P450s, including Cyp1a2 (Mm00487224_m1), Cyp2b10 (Mm01972453_s1), Cyp3a11 (Mm00731567_m1), and Cyp4a10 (Mm02601690_gH); carnitine palmitoyl transferase 1A (Cpt1α) (Mm01231183_m1); peroxisome proliferator-activated receptor alpha (Pparα) (Mm00440939_m1); Cd36 (Mm01135198_m1); fatty acid-binding protein 1 (Fabp1) (Mm00444340_m1); fatty acid
synthase (Fasn) (Mm00662319_m1); stearoyl coenzyme A desaturase1 (Scd1) (Mm00772290_m1); Pnpla3 (Mm00504420_m1); fibroblast growth factor 21 (Fgf21) (Mm00840165_g1); insulin-like growth factor 1 (Igf1) (Mm00439560_m1); betatrophin (Mm01175863_g1), glucose 6-phosphate (G6P) (Mm00839363_m1); phosphoenolpyruvate carboxy kinase (Pck1) (Mm01247058_m1); insulin 1(Mm01950294_s1); Nkx6-1 (Mm00454961_m1); NR4a1 (Mm01300401_m1); NR4a3 (Mm00450071_g1); pancreatic polypeptide (Mm00435889_m1); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Mm99999915_g1). All reactions were run in triplicate. The relative expression of each mRNA was calculated using the comparative 2^(-ΔΔCt) method and was normalized against GAPDH mRNA.

Measurement of hepatic lipid

The liver tissues were rinsed in neutral 1× phosphate buffered saline (PBS) and homogenized in 50 mM NaCl solution. Hepatic lipids were extracted by a mixed solution of chloroform and methanol (2:1) according to a published protocol (101). Total lipid extracts were dried using nitrogen before they were dissolved in PBS containing 1 % triton X-100. Hepatic triglycerides and free fatty acid contents were measured using commercial kits and normalized to liver weight.

Measurement of plasma lipid and cytokine

Blood samples were collected by syringe with anti-coagulated EDTA. Plasma was obtained after centrifugation at 3,000 rpm for 20 min at 4 °C. Plasma ALT, AST, triglyceride, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDH), very low-density lipoprotein (VLDL), and non-HDL cholesterol (nHDLc) levels were measured by Piccolo Xpress Chemistry Analyzer using the lipid panel plus kits. Plasma
cytokine and adipokine levels were measured on a Luminex® 100 system using a customized Milliplex® MAP mouse adipokine Panel.

Statistical analysis

Statistical analyses were carried out using SigmaPlot 11.0 software (Systat Software Inc., San Jose, CA). Data are presented as mean ± SEM. Statistical evaluation of the data was performed using two-way analysis of variance (ANOVA). Fold-changes are fold of vehicle control group. For all statistical comparisons, p-values less than 0.05 were considered statistically significant.
3. Results

Effects of PCB exposures on body weight and composition

There were no significant changes in body weight in either group (Fig. 2.1 A). Regarding body composition, there were no significant trends towards increased percent body fat with Aroclor 1260 (14.0 %) or PCB 126 (7.5 %). The interaction between Aroclor 1260 and PCB 126 significantly decreased percent body fat in the DL/NDL-PCBs mixture-treated group compared to either alone exposure (Fig. 2.1 B). No significant changes were observed in the liver/body weight ratio (Fig. 2.1 C) or the epididymal fat/body weight ratio (Fig. 3.1 D).
Figure 2.1 Effects of PCB exposures on liver and fat weight. (A) The body weight, (B) body fat composition, (C) the ratio of liver weight to body weight, (D) the ratio of epididymal fat weight to body weight. Data are presented as mean ± SEM. n=10. p<0.05, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatic expression of AhR, CAR, PXR, and their target genes

To determine if PCB exposures affected mRNA expression of hepatic xenobiotic receptors (AhR, CAR, PXR) and their target genes, hepatic mRNA expression was measured by RT-PCR. AhR mRNA expression was significantly decreased by either Aroclor 1260 (3.3-fold) or PCB 126 (3.2-fold) exposure, while the Aroclor 1260/PCB 126 mixture significantly increased AhR mRNA expression compared to either exposure alone (Fig. 2.2 A). PCB 126 alone (8.7-fold) or the Aroclor 1260/PCB 126 mixture (7.9-fold) activated AhR, as indicated by increased AhR target gene Cyp1a2 mRNA expression. The latter data suggest that the observed changes in the AhR mRNA expression levels did not affect its transcriptional activity (Fig. 2.2 B). CAR mRNA expression was slightly increased by PCB 126 alone or by the Aroclor 1260/PCB 126 mixture, but was not changed by Aroclor 1260 (Fig. 2.2 C). The CAR target gene Cyp2b10 mRNA expression was robustly increased by Aroclor 1260 (130,000-fold), while PCB 126 induced Cyp2b10 mRNA expression to a much lower degree (25.0-fold). An interaction between Aroclor 1260 and PCB 126 resulted in significantly different Cyp2b10 mRNA levels that were intermediate between either exposure alone (50,000-fold) (Fig. 2.2 D). PXR mRNA expression was significantly decreased by either Aroclor 1260 or PCB 126 exposures, but was increased by the Aroclor 1260/PCB 126 mixture compared to either exposure alone (Fig. 2.2 E). PXR-dependent gene Cyp3a11 mRNA expression was increased by Aroclor 1260 (2.0-fold), and exposure with the Aroclor 1260/PCB 126 mixture attenuated this effect (Fig. 2.2 F). These results demonstrate that PCB 126 alone or in the DL/NDL-PCBs mixture activated AhR, and Aroclor 1260 potently activated CAR and to a lesser degree PXR. The PCB exposures differentially regulated AhR and nuclear receptor expression.
Moreover, the results suggested that PCB 126 activated AhR may suppress the activation of CAR and PXR by Aroclor 1260. However, the reciprocal effect of activating either CAR or PXR did not appear to affect AhR activity.
Figure 2.2 Effects of PCB exposures on levels of hepatic AhR, CAR, PXR, and their target genes expression. Hepatic mRNA levels of AhR (A) and target gene Cyp1a2 (B), CAR (C) and target gene Cyp2b10 (D), PXR (E) and target gene Cyp3a11 (F) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatic lipids

To evaluate for hepatic steatosis, histologic staining (H&E) of liver was performed. PCB 126, but not Aroclor 1260 exposure, induced mild small droplet-macrovesicular steatosis. PCB 126-induced hepatic steatosis was attenuated in the DL/NDL-PCBs mixture (Fig. 2.3 A). These histologic steatosis results were confirmed by biochemical lipid assays. The hepatic triglyceride levels (30.7 %) (Fig. 2.3 B) and free fatty acid levels (approximately 60.0 %) (Fig. 2.3 C) were increased by PCB 126 exposure, but exposure with the mixture of Aroclor 1260 plus PCB 126 abrogated this affect. Aroclor 1260 exposure had no effect on either hepatic triglycerides or free fatty acids (Fig. 2.3 B&C). Significant hepatic necroinflammation was not observed under any exposure in histology (Fig. 2.3 A); plasma alanine or aspartate aminotransferase levels (Fig. 2.3 D&E); or serum pro-inflammatory cytokines (IL-6, MCP-1, PAI-1) were not significantly altered within any exposure group (Fig. 2.3 F-H).
Figure 2.3 Effects of PCB exposures on hepatic lipids. (A) H&E staining of liver, (B) hepatic triglycerides levels, (C) hepatic free fatty acid levels, plasma levels of (D) ALT, (E) AST, (F) IL6, (G) MCP1, and (H) PAI1. n=10. Data are presented as mean ± SEM. p<0.05, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on plasma lipids

The PCB exposures had very different effects on plasma lipids. While PCB 126 increased hepatic lipids, it significantly decreased plasma triglycerides, total cholesterol, HDL, VLDL, and nHDLc cholesterol (Fig. 2.4 A-E). Blood lipids were not affected by Aroclor 1260 either alone or in the DL/NDL-PCBs mixture. In summary, these data suggested that subacute, low-dose PCB 126 exposure caused toxicant-associated fatty liver disease (steatosis) without significant necroinflammation. The fatty liver disease was associated with a paradoxical decrease in blood lipids. Aroclor 1260 in the DL/NDL-PCBs mixture abrogated PCB 126-induced changes in liver, but not the blood lipid profile.

Figure 2.4 Effects of PCB exposures on plasma lipid levels. (A) Plasma triglyceride, (B) cholesterol, (C) high-density lipoprotein (HDL), (D) very low-density lipoprotein (VLDL), and (E) non-HDL cholesterol (nHDLc) levels were measured by Piccolo Xpress chemical analyzer (n=8-10). Data are presented as mean ± SEM. p<0.05, b= PCB 126 effects.
Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression

Since PCB 126 exposure impacted liver and blood lipid levels, expression of lipid oxidation genes (PPARα and its targets, Cyp4a10 and Cpt1α) were measured. There was a trend towards increased Ppara mRNA expression by both PCB 126 and Aroclor 1260, but the mixture of both PCB types significantly decreased Ppara mRNA expression compared to either alone (Fig. 2.5 A). Both mRNA levels of Cpt1a (1.5-fold, Fig. 2.5 B) and Cyp4a10 (1.2-fold, Fig. 2.5 C) were significantly increased by PCB 126. Neither Cyp4a10 nor Cpt1a mRNA expression was changed by Aroclor 1260 exposure. However, the DL/NDL-PCBs mixture increased Cyp4a10 mRNA expression (Fig. 2.5 C), while decreasing Cpt1a mRNA expression (Fig. 2.5 B) compared to PCB 126 exposure alone. Thus, PCB 126 exposure activated PPARα to induce expression of genes implicated in hepatic fatty acid β-oxidation. While this may have contributed to the observed hypolipidemic effects of PCB 126, it cannot account for the increased hepatic lipid levels and steatosis observed with this exposure. Likewise, the decrease in hepatic PPARα and Cpt1α mRNA expression cannot account for the decreased hepatic steatosis observed when Aroclor 1260 was given along with PCB 126.
Figure 2.5 Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression. Hepatic mRNA levels of Cyp4a10 (A), Cpt1α (B), and Ppara (C) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on other genes of hepatic lipid metabolism

Because PCB 126 induced hepatic steatosis that could not be explained by a reduced β-oxidation, expression of other hepatic lipid metabolism genes was measured. These genes were involved in hepatic fatty acid import (Cd36 and Fabp1), synthesis (Fasn), desaturation (Scd1), and also included the lipase implicated in NAFLD, Pnpla3. Cd36 mRNA levels were significantly induced by either PCB 126 (350.0-fold) or Aroclor 1260 (300.0-fold) exposures, but surprisingly exposure to the Aroclor 1260/PCB 126 mixture attenuated these effects compared to either alone (Fig. 2.6 A). Likewise, either PCB 126 (1.5-fold) or Aroclor 1260 (1.3-fold) exposures significantly increased the mRNA levels of lipid transporter Fabp1, but Aroclor 1260/PCB 126 co-administration reduced Fabp1 expression compared to either exposure alone (Fig. 2.6 B). Interestingly, there was nearly the mirror image observed between Cd36/Fabp1 and Fasn mRNA expression. Fasn mRNA expression was significantly decreased by either Aroclor 1260 (3.3-fold) or PCB 126 (5.0-fold) exposures, but was increased by the mixture of Aroclor 1260 plus PCB 126 compared to either exposure alone (Fig. 2.6 C). Thus, mono-exposure to either PCB 126 or Aroclor 1260 increased hepatic lipid uptake while decreasing lipid biosynthesis, but these effects were abrogated by exposure to the NDL/DL-PCBs mixture. Thus, the increased steatosis observed with PCB 126 exposure was most likely due to increased hepatic lipid uptake despite decreased de novo lipid biosynthesis and increased β-oxidation.

Exposure with either Aroclor 1260 (1.4-fold), PCB 126 (1.7-fold), or Aroclor 1260/PCB 126 (2.3-fold) resulted in significant down-regulation of Scd1 mRNA levels (Fig. 2.6 D). This should increase the relative abundance of saturated fatty acids compared to unsaturated fatty acids. A loss of function polymorphism in the hepatic lipase, PNPLA3,
results in the accumulation of mutant protein on lipid droplets to increase human NASH (102). *Pnpla3* mRNA expression was significantly induced by Aroclor 1260 (3.0-fold) exposure, but was suppressed by either PCB 126 (2.3-fold) or Aroclor 1260/PCB 126 (7.7-fold) exposure (Fig. 2.6 E). While the impact of these effects on steatohepatitis in rodents expressing wild type Pnpla3 may not impact the degree of steatosis, the induction of mutant human PNPLA3 by Aroclor 1260 is predicted to increase NASH, while the suppression of the mutant human PNPLA3 by the other exposures is predicted to be protective (102). Pnpla3 expression may be regulated by both CAR (103) and the AhR (104). Our data suggested that there may be interaction between Aroclor 1260-activated CAR and PCB 126-activated AhR effecting the expression of Pnpla3. In summary, while all PCB exposures disrupted normal hepatic lipid metabolism, only PCB 126 exposure induced steatosis.
Figure 2.6 Effects of PCB exposures on genes expression of hepatic lipid metabolism.

Hepatic mRNA levels of *Cd36* (A), *Fabp1* (B), *Fasn* (C), *Scd1* (D), and *Pnpla3* (E) were measured by performing RT-PCR. Data are presented as mean ± SEM. \( n=10 \). \( p<0.05 \), a= Aroclor 1260 effects, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatokine expression

The liver also functions as an endocrine organ that plays a major role in the development of obesity, diabetes, and metabolic syndrome. Hepatic mRNA expression levels of several protective hepatokines previously implicated in these processes (e.g., Fgf21, Igf1, and betatrophin) were measured. The Fgf21 mRNA expression was significantly down-regulated by either Aroclor 1260 (10.0-fold) or PCB 126 (4.0-fold) exposure compared to control groups. In contrast, administration of Aroclor 1260/PCB 126 mixture increased Fgf21 mRNA expression compared to either alone (Fig. 2.7 A). Hepatic Igf1 mRNA expression was significantly increased after exposure with either Aroclor 1260 (1.2-fold) or PCB 126 (1.6-fold) compared to control groups, while Aroclor 1260/PCB 126 mixture administration resulted in a reduction of Igf1 mRNA expression compared to either alone (Fig. 2.7 B). Although it is controversial whether betatrophin promotes islet β cells expansion (105, 106), the expression of betatrophin mRNA was affected by PCBs exposure. Aroclor 1260 exposure (2.1-fold) significantly induced betatrophin mRNA expression, but not by PCB 126 exposure. Mixture of PCB 126 of Aroclor 1260 abolished Aroclor 1260-induced betatrophin mRNA expression (Fig. 2.7 C). These results suggested that environmental PCBs exposure may disrupt the liver-pancreas axis, leading to the development of NAFLD/NASH and diabetes. In summary, Aroclor 1260 increased mRNA expression of Igf1 and betatrophin while decreasing mRNA expression of Fgf21. Addition of PCB 126 to Aroclor 1260 produced the opposite effects. PCB 126 exposure alone increased Igf1 and decreased Fgf21 mRNA expression. These results demonstrated that the liver is a causal target organ for PCB-related endocrine disruption.
Figure 2.7 Effects of PCB exposures on hepatokines expression. Hepatic mRNA levels of $Fgf21$ (A), $Igf1$ (B), and $betatrophin$ (C) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on pancreas structure

Because PCB exposures have been associated with diabetes, the effects of the PCB exposures on the pancreatic structure were evaluated. The pancreas weight to body weight ratio was unaffected by either Aroclor 1260 or PCB 126 exposures (Fig. 2.8 A). However, it was significantly decreased (25.3 %) by Aroclor 1260 / PCB 126 co-exposure (Fig. 2.8 A). H&E staining demonstrates pancreatic structural changes following exposure with the NDL/ DL PCB mixture (Fig. 2.8 B). Specifically, this co-exposure was associated with pancreatic degeneration with acinar cell steatosis and atrophy occurring in the absence of ductal changes or inflammation. These changes did not occur with the other PCB exposures (Fig. 2.8 B). To further evaluate the pancreatic pathology associated with Aroclor 1260/PCB 126 co-exposure, trichrome stain was performed. The co-exposed mice had mildly increased pancreatic fibrosis compared to mice treated with vehicle control (Fig. 2.8 C).
Figure 2.8 Effects of PCB exposures on pancreatic structure. (A) The ratio of pancreas weight to body weight, (B) H&E staining of pancreas (20 ×), and (C) trichrome staining (40 ×). Blank arrow indicates lipid droplet and blank star means degeneration in pancreas. c= interaction between Aroclor 1260 and PCB 126.
Effect of PCB exposures on pancreatic function

The pancreatic insulin 1 mRNA expression was significantly up-regulated by either Aroclor 1260 (5.8-fold) or PCB 126 (1.4-fold) exposure, but was significantly down-regulated by the Aroclor 1260/PCB 126 mixture (0.25-fold) (Fig. 2.9 A). A similar pattern was seen for the beta cell identity gene, Nkx6-1 (Fig. 2.9 B), and for the F-cell gene product, pancreatic polypeptide (Fig. 2.9 C). The nuclear receptors NR4a1 and NR4a3 are involved in Nkx6-1 regulated islet beta cell proliferation (107). As with mRNA expression of Nkx6-1, the mRNA expression levels of NR4a1 and NR4a3 were increased by either Aroclor 1260 (2.0-fold and 3.1-fold, respectively) or PCB 126 (1.8-fold and 3.0-fold, respectively), while the Aroclor 1260/PCB 126 exposure reduced NR4a1 and NR4a3 mRNA expression compared to either exposure alone (Fig. 2.9 D&E). These findings demonstrate that exposure to the NDL/DL-PCB mixture was associated with decreased expression of genes regulating pancreatic beta cell identity, and this was associated with decreased expression of insulin and pancreatic polypeptide, and pancreatic histopathologic changes.
Figure 2.9 Effects of PCB exposures on pancreatic gene expression. Pancreatic mRNA levels of *insulin1* (A), *Nkx6-1* (B), *pancreatic polypeptide* (C), *NR4a1* (D) and *NR4a3* (E) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatic gluconeogenic gene expression

Hepatic gluconeogenesis, contributes significantly to glycaemia, particularly in the fasting state. The hepatic mRNA level of \( Pck1 \), a regulator of gluconeogenesis, was significantly increased by PCB 126 exposure (1.6-fold), but was down-regulated by the Aroclor 1260/PCB 126 mixture (Fig. 2.10 A). The hepatic gluconeogenic gene, \( G6P \) mRNA, was significantly down-regulated by either Aroclor 1260 (1.7-fold) or PCB 126 (1.3-fold) exposure compared to vehicle control group; while the Aroclor 1260/PCB 126 mixture up-regulated \( G6P \) mRNA expression compared to either exposure alone (Fig. 2.10 B). Thus, hepatic carbohydrate metabolism was also affected by PCB exposures. Perhaps consistent with decreased hepatic gluconeogenesis, the fasting blood glucose was decreased by PCB 126 exposure, either alone or along with Aroclor 1260 (Fig. 2.10 C).

![Figure 2.10](image)

**Figure 2.10** Effects of PCB on gluconeogenic genes expression. Hepatic mRNA levels of gluconeogenic genes \( G6P \) (A) and \( Pck1 \) (B) were measured by performing RT-PCR. (C) Fasting blood glucose. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects; C= interaction between Aroclor 1260 and PCB 126.
4. Discussion

The exposure protocol to Aroclor 1260 used in this study is the same, which we have used in previous 12-week studies (59, 108). This exposure was designed to mimic the PCB bioaccumulation pattern and the highest levels of exposure seen in humans (52). However, Aroclor 1260 has lower levels of DL-PCBs than in human bioaccumulation patterns. To compensate for lower levels of DL-PCBs, we added a small quantity of PCB 126 that represents approximately 0.02% of a human’s total PCB exposure based on NHANES data (42). Because PCB 126 is not the only DL-PCB and human exposures vary, the PCB 126 dose was increased to 0.1% (20 μg/kg).

This PCB 126 dose is much lower (20 μg/kg) than that used in other studies (1.6 mg/kg) in the literature (48), but it was sufficient to activate the prototypical AhR target gene, Cyp1a2. The induction of Cyp1a2 mRNA was equal in both the PCB 126 alone group and in the Aroclor 1260/PCB 126 mixture-exposed groups. This confirms our previous results that Aroclor 1260 at this dose does not activate AhR (59), most likely due to the low levels of DL-PCBs in the commercial Aroclor 1260 mixture.

Activation of CAR can either occur from direct by ligand binding or indirect activation via inhibition of EGFR (95). The consequences of the different modes of activation of CAR are significant as direct CAR activation may have more limited effects in the cell than indirect activation. PCB dependent inhibition of EGFR signaling causes extensive changes in the mouse phosphoproteins, which includes PI3K, ERK, STAT3, raf (93). In this study, all exposures increased CAR target gene Cyp2b10 mRNA expression. The increases were far greater with Aroclor 1260 or the Aroclor 1260/PCB 126 mixture exposure > 1000-fold while PCB 126 exposure increased Cyp2b10 mRNA expression a more modest 20-fold.
This most likely reflects the large difference in dose (mg vs. µg), but confirms our observation that PCB 126 is a good inhibitor of EGFR (94). Interestingly, the induction of Cyp2b10 mRNA by Aroclor 1260 alone was greater than the induction by the Aroclor 1260/PCB 126 mixture, indicating that mixtures do not behave in the same way as either PCB preparation alone. These results suggest that activation of AhR affected other PCB-regulated transcription factors. Similar results were obtained with Cyp3a11, where only Aroclor 1260 induced this gene and the effects of the mixture appeared no different than that seen in the control animals. Thus, it appears that there is interaction between the AhR and the nuclear receptors, CAR and PXR.

The effects of the various PCB exposures on biomarkers of liver disease are more complex. Exposure to PCB 126 alone increased liver triglycerides and free fatty acids, while the addition of Aroclor 1260 reduced liver triglycerides and fatty acids to close to control levels. This is consistent with previous studies in the literature demonstrating that activation of AhR in mice spontaneously induced hepatic steatosis (70, 71) and caused mice to be much more sensitive to methionine choline-deficient (MCD)-induced NASH (109). Likewise, this is consistent with our previous 12-week study in Aroclor 1260 exposed animals in which steatosis did not get worse. However, Aroclor 1260 exacerbated steatohepatitis in 42 % calories from fat mice but had little effect on 10.2 % calories from fat control diet. In contrast, direct activators of CAR, such as TCPOBOP, decrease hepatic steatosis in HFD-fed type 2 diabetic models and in the ob/ob mice (85, 86). All of these data likely reflect the different modes of activation of CAR as PCBs in murine systems are indirect activators.
Activation of the AhR is known to be associated with dyslipidemia and a wasting syndrome. In our current study we observed reductions in serum cholesterol and both HDL and nHDLc form, suggesting both increased hepatic import and decreased secretion. Likewise, serum triglycerides and VLDL were also reduced. This is consistent with a wasting syndrome in which peripheral fat is being mobilized and steatosis results. Interestingly, these affects occur in all groups that received PCB 126 and are independent of effects caused by Aroclor 1260 exposure. The hypolipidemia induced by PCB 126 exposure is clearly different from the steatosis caused by hypercaloric diets where these parameters rise in concert with the development of steatosis.

The effects of each exposure on genes involved in lipid metabolism are also more complex. For example, the mixture of PCB 126 and Aroclor 1260 slightly decreased the level of PPARα, while PCB 126 slightly induced CPT1a and Cyp4a11, and the mixture slightly attenuated the effect with CPT1a. In fact, it augments the effect with Cyp4a11. Thus, it is highly unlikely this is a PPARα-dependent process but more likely other transcription factors are involved in the promoters of these gene are involved.

Many other genes involved in fat mobilization are affected by PCB exposure. As anticipated from previously published studies exposure to either Aroclor 1260 or PCB 126 induced mRNA expression of Cd36. Interestingly, the mixture of both of these exposures actually reduced the expression of this gene that may in part explain why the steatosis was less pronounced in the Aroclor 1260/PCB 126 mixture group. A similar pattern is observed in the Fabp1 mRNA expression, suggesting a conservation of mechanism while the opposite pattern is observed with Fasn. Other genes in fat metabolism and disposition are also affected including Scd1, which is negatively regulated by both Aroclor 1260 and PCB.
126 in a simple additive fashion suggesting independent mechanisms. Finally, the mutated Pnpla3 gene results in accumulated lipids and inhibited VLDL secretion. These mutant versions are strongly linked to the development of NASH in the human population. This gene is induced by Aroclor 1260, but suppressed by PCB 126 and the combination of both suppresses the mRNA expression further. In concert these results clearly demonstrate that mixtures of DL/NDL-PCBs mixture do not act like their individual components and that considerable crosstalk exists between these signaling mechanisms.

In our study, NDL/DL-PCB mixtures definitely caused structural alterations in pancreas, as indicated by pancreatic fibrosis, acinar atrophy and acinar cell steatosis. However, there was no definite evidence of diabetes (normal HOMA-B, and decreased fasting glucose). Regarding translation to human disease, acinar cell steatosis has not been described in humans. However, PCB mixtures seem to cause a pancreatopathy, similar to that seen in diabetes, named diabetic exocrine pancreatopathy (110), and also exposures to pancreato-toxins such as smoking and alcohol, neither of which is associated with diabetes. We propose the term PCB-induced pancreatopathy to describe this condition. Just as in other forms of pancreatopathy, the clinical significance of the findings need further study. The unchanged HOMA-B in mice may be due to sufficient beta cell reserve at this timepoint in mice that were not stressed by obesity. The histological changes were paralleled by decreased mRNA expression of insulin 1, pancreatic polypeptide, and islet identity factors (e.g., Nkx6-1, NR4a1, and NR4a3). The combination of molecular and histological changes suggest that the Aroclor 1260/PCB 126 mixture exerted pancreatic endocrine and exocrine toxicity. However, neither Aroclor 1260 nor PCB 126 alone demonstrated this pancreatic toxicity. These results are broadly consistent with those of
earlier studies in which long-term PCB 126 exposure caused early β-cell failure (111). Lin et al. reported that chronic exposure to Aroclor 1254, caused pancreatic atrophy by reducing proliferation (112). Aroclor 1254 altered islet β-cell mass and impaired insulin receptor signaling, and ultimately disrupted glucose homeostasis (113). Our findings extend these observation by demonstrating that PCB exposure can possibly affect the genetic programing responsible for islet differentiation and function (e.g. islet identity factors). The islet identity factors are transcription factors involved in pancreatic differentiation and beta cell homeostasis in utero and in the adult. In rat islets, Nkx6-1 regulates the expression of glucagon, and controls glucose-stimulated insulin secretion (GSIS) (114). The alteration of Nkx6-1 expression was observed in type 2 diabetes patients (115). These results suggest alteration of islet identity factors may be involved in endocrine disruption by endocrine and metabolism disrupting chemicals (EDCs/MEDs) exposure. In the present study, the observed islet identity factors changes were a novel finding in PCB exposed mice, and more work is required to determine mechanisms of action.

Hepatokines have been proposed as being involved in mechanisms involved in the development of diabetes, as well as, NAFLD/NASH. These hepatokines include FGF21, IGF1 and betatrophin. FGF21 is a member of fibroblast growth factors (FGF) family, and plays a critical role in regulation of obesity, insulin resistance and fatty liver disease (116) by increasing brown adipose levels and adiponectin secretion. In the current study, mRNA levels of Fgf21 were downregulated in both Aroclor 1260 and PCB 126 treated groups, while Aroclor 1260/PCB 126 mixture exposure resulted in increased Fgf21 mRNA levels compared to individual exposures. As our mice were fasted, the Fgf21 expression in the
PCB 126-exposed mice is consistent with the concept that AhR induces FGF21 in the fed-state, but suppresses FGF21 in the fasted-state (117).

Another hepatokine that has been implicated both in diabetes and the control of serum triglycerides and LDL metabolism is betatrophin (ANGPT8) as reviewed (118). Betatrophin expression is low in fasted animals and rises in the fed state and regulates triglyceride metabolism (119) by inhibiting lipoprotein lipase (LPL), thereby, decreasing LDL and VLDL uptake by adipocytes. The functions of betatrophin in diabetes are controversial but studies suggest it promotes pancreatic β cell proliferation, expanding β cell mass, and improves glucose tolerance (105). Regardless, in the current study, expression of betatrophin mRNA was significantly upregulated by Aroclor 1260 exposure, but not by PCB 126 exposure. Adding PCB 126 to Aroclor 1260 abolished Aroclor 1260-induced betatrophin expression. PCBs exposure-induced dysregulation of hepatokines clearly demonstrates that PCBs and potentially other endocrine and metabolism disrupting chemicals (EDCs/MDCs) may affect expression of those hepatokines, such as FGF21 and betatrophin.

In conclusion, even an exposure as low as 20 µg/kg of PCB 126 induced AhR-dependent genes in mouse liver. Mixtures of DL and NDL PCBs exhibited different effects on gene expression, fatty liver disease, and diabetes endpoints, likely due to receptor interaction with each other. This suggests that studying single congeners in isolation may lead to potentially misleading results when modeling the metabolic disease associated with human PCB exposures. PCB 126 produced phenotypically were liver disease, while exposure to the mixture of PCB 126 plus Aroclor 1260 induced were pancreatic disease. Several novel targets for endocrine/metabolic disruption were identified including
PNPLA3, islet identity factors, and hepatokines. The latter implied that the liver is both a target and effect organ for endocrine disruption. More research is required to better understand the molecular mechanisms involved in complex mixtures of EDCs/MEDs, including DL/NDL-PCB mixtures.
CHAPTER III
THE INTERACTION OF DIET AND POLYCHLORINATED BIPHENYLS IN
REGULATION OF NON-ALCOHOLIC STEATOHEPATITIS

1. Introduction

High calorie intake or a Western diet induces NAFLD, and environmental pollutants serve as “second hit” to exacerbate high fat diet-induced liver injury in murine models (37). For example, a 20 mg/kg exposure to Aroclor 1260 has no effect on liver injury and hepatic pathological changes in control diet fed mice, but a high fat diet fed mice developed neutrophil infiltration, liver injury. Thus, Aroclor 1260 drives hepatic steatosis progression to steatohepatitis in high fat diet fed mice. Moreover, a high fat diet suppresses CAR activation, and decreases its target genes’ expression induced by Aroclor 1260 exposure. Our acute exposure results demonstrated either Aroclor 1260 or PCB 126 exposure affected hepatic lipid metabolism, while only PCB 126 exposure induced mild hepatic steatosis. Co-administration of Aroclor 1260 and PCB 126 reduced the mild steatosis. With the increasing incidence of obesity and type 2 diabetes patients worldwide, a higher incidence of NAFLD is being observed, and the role of PCB exposures in these require investigation (42). The purpose of this chronic exposure study was to perform an analysis of liver and serologic endpoints using exposures that better mimic a high level human exposure to examine if the murine AhR is preferentially activated and whether or not mixtures of DL- and NDL-PCBs will behave like each component alone in high fat diet fed mice will be investigated. The animal groups and PCB treatments were the same as the acute exposure
study, but the control diet was replaced by high fat diet, and mice were exposed for 12 weeks.
2. Materials and Methods

Reagents

Please refer to Chapter 3 section for details. Humulin R (100 U/mL) was obtained from Eli Lilly, (Indianapolis, IN). Primary antibody (F4/80, ab6640) and second antibody were supplied by Abcam, (Cambridge, MA). CAE, Naphthol AS-D Chloroacetate (Specific Esterase) Kit were obtained from Sigma-Aldrich, (St. Louis, MO).

Animal exposures

The animal protocol used was approved by the University of Louisville Institutional Animal Care and Use Committee. Male C57BL/6j mice (10 weeks old) were obtained from The Jackson Laboratory, (Bar Harbor, ME), and divided into 4 groups (n=10). All the mice were fed a high fat diet (15.2 %, 42.7 %, and 42.0 % of total calories come from protein, carbohydrate, and fat, TekLab TD88137). Mice were treated by one-time gavage with either Aroclor 1260 (20 mg/kg), PCB 126 (20 µg/kg), Aroclor 1260 (20 mg/kg) with 0.1 % PCB 126 (20 µg/kg) or vehicle control (corn oil) for 12 weeks. Glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed at 8 and 10 weeks, respectively, prior to euthanasia. Mice were housed in a temperature- and light controlled-room (12 h light; 12 h dark) with food and water ad libitum. The animals were euthanized at the end of week 12 using ketamine/xylazine (100/20 mg/kg body weight, i.p.) and the blood, liver, and fat tissues were collected. Dual energy X-ray absorptiometry (DEXA) scanning (Lunar PIXImus densitometer, WI) was performed to analyze body fat composition prior to euthanasia.
Histological staining

Please refer to Chapter 3 section for detail. Additional chloroacetate esterase activity and macrophage accumulation were measured using CAE and immunohistochemistry (IHC) staining according to manufacturer’s protocols, respectively.

Real-time PCR

Please refer to Chapter 3 section for detail. Additional probes and their sequence were as follows: Tgf-β1 (Mm01178820_m1), Acta2 (Mm00725412_s1), Collagen (Col) 1a1 (Mm00801666_g1), Collagen (Col) 1a2 (Mm00483888_m1), and TIMP1 (Mm00441818_m1).

Measurement of hepatic lipid

Please refer to Chapter 3 section for detail.

Measurement of plasma lipid and cytokine

Please refer to Chapter 3 section for detail.

Glucose and insulin tolerance test

For the glucose tolerance test, mice were fasted for 16 hours prior to test. The basal fasting blood glucose levels were measured using a glucometer (ACCU-CHECK Aviva, Roche, Basel, Switzerland) with one drop of tail vein blood. Then sterile glucose was administrated via intraperitoneal (i.p.) injection at dose of 1 g/kg body weight within 15 minutes, and blood glucose levels were measured at 15, 30, 60, and 120 minutes post injection.

For the insulin tolerance test, mice were fasted for 6 hours at the day of test. Following a determination of the basal glucose level, sterile insulin was administrated, via
intraperitoneal (i.p.) injection, at dose of 0.5 U/kg body weight within 15 minutes, and blood glucose levels were measured at 15, 30, 60, and 120 minutes post injection.

Statistical analysis

Please refer to Chapter 3 section for detail.
3. Results

Effects of PCB exposures on body weight and composition

AhR activation induced by a high dose of pollutant agonist exposure, such as TCDD, leads to a wasting syndrome, characterized by a loss of body weight associated with a decrease in adipose tissue mass (120). To evaluate whether PCB exposures induced a wasting syndrome, body weight was monitored weekly. The body weight gradually increased in all groups regardless of PCB exposures due to high fat diet used in this experiment (Fig. 3.1 A). However, there were no changes in body weight (Fig. 3.1 B) or fat composition (Fig. 3.1 C) in PCB exposure groups compared to control group. The liver/body weight ratio was not changed after PCB exposures (Fig. 3.1 D); and the epididymal fat/body weight ratio was increased only after Aroclor 1260 exposure, but not in other PCB exposed groups (Fig. 3.1 E).
Figure 3.1 Effects of PCB exposures on body weight and composition after 12 weeks exposure. (A) Body weight changing, (B) body weight, (C) body fat composition, (D) the ratio of liver weight to body weight, (E) the ratio of epididymal fat weight to body weight. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects.
Effects of PCB exposures on AhR, CAR and their target genes

As shown in chapter 2, different types of PCB exposures are associated with AhR and CAR activation in mice fed control synthetic diet. AhR mRNA expression was decreased by PCB 126 (0.5-fold) exposure, but not by the other PCB exposed groups (Fig. 3.2 A). PCB 126 alone or Aroclor 1260/PCB 126 mixture activated AhR, as indicated by 4.0-fold or 2.6-fold induction of the AhR target gene Cyp1a2 mRNA expression, respectively. Adding PCB 126 to Aroclor 1260 resulted in a reduction of Cyp1a2 mRNA expression compared to PCB 126 alone (Fig. 3.2 B). CAR mRNA expression was significantly increased by PCB 126 alone (1.6-fold) or in the Aroclor 1260/PCB 126 mixture (2.3-fold), but was not changed by Aroclor 1260 (Fig. 3.2 C). The CAR-dependent gene Cyp2b10 mRNA was increased by Aroclor 1260 (6.5-fold) or Aroclor 1260/PCB 126 mixture (2.3-fold) exposure (Fig. 3.2 D). Addition of PCB 126 reduced the Aroclor 1260-dependent induction of Cyp2b10, indicating an interaction between AhR and CAR signaling (Fig. 3.2 D). However, the extent of AhR or CAR transcriptional activities were affected by diet effects, since high fat diet suppressed PCB exposures-induction of the AhR target Cyp1a2 slightly (≈50%). As anticipated (37), decreased induction CAR-target Cyp2b10 dramatically (≈1000-fold) activity when compared with control synthetic diet fed mice treated with same dose of PCBs. Moreover, the conclusions made in chapter 2 that the reciprocal effects of AhR and nuclear receptor were also found in the current study.
Figure 3.2 Effects of PCB exposures on AhR, CAR and their target genes. Hepatic mRNA levels of *AhR* (A) and target gene *Cyp1a2* (B), *CAR* (C) and target gene *Cyp2b10* (D) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatic steatosis

H&E staining data demonstrated mice fed on high fat diet developed variable, centrilobular, macrovesicular lipidosis (hepatic steatosis), and PCB exposures did not exacerbate high fat diet-induced hepatic steatosis (Fig. 3.3 A). Neither hepatic triglyceride (Fig. 3.3 B) nor cholesterol (Fig. 3.3 C) levels were significantly affected by either PCB exposures, however, hepatic free fat acid levels were significantly increased by PCB 126 (1.3-fold) alone or Aroclor 1260/PCB 126 mixture (1.5-fold) exposures (Fig. 3.3 D).
Figure 3.3 Effects of PCB exposures on hepatic steatosis. (A) H&E staining of liver (10 ×). High fat diet induced variable, centrilobular, macrovesicular lipidosis, and PCBs exposure did not exacerbate high fat diet-induced steatosis in liver. (B) hepatic triglycerides levels, (C) hepatic cholesterol levels, (D) hepatic free fatty acid levels. n=10. Data are presented as mean ± SEM. p<0.05, b= PCB 126 effects.
Effects of PCB exposures on liver injury

Previous studies showed that Aroclor 1260 exposure serves as “second hit” to drive hepatic steatosis to advanced steatohepatitis, therefore, plasma alanine (ALT) or aspartate (AST) aminotransferase levels were measured. Plasma ALT levels were elevated by Aroclor 1260 alone exposure (1.9-fold), but not by PCB 126 exposure. The mixture of PCB 126 and Aroclor 1260 attenuated Aroclor 1260-elevated plasma ALT levels (Fig. 3.4 A), suggesting that PCB 126 was protective against liver injury in this model. Likewise, PCB 126 exposure also showed a suppression of plasma AST levels when either given alone or mixed with Aroclor 1260 (Fig. 3.4 B). Hepatic mRNA expression of Tnfa was increased by either Aroclor 1260 exposure (1.8-fold) or Aroclor 1260/PCB 126 mixture exposure (1.9-fold) compared to vehicle group (Fig. 3.4 C). Likewise, hepatic mRNA expression of Ccl8 was significantly induced by Aroclor 1260 exposure (3.3-fold), suppressed by PCB 126 alone exposure (0.38-fold), and mixture of PCB 126 of Aroclor 1260 abolished Aroclor 1260 exposure-induced Ccl8 mRNA expression (Fig. 3.4 D). The similar patterns of mRNA levels of Ccl3 (Fig. 3.4 E) and Cxcl1 (Fig. 3.4 F) were also observed. In concert, these results demonstrated that addition of PCB 126 attenuates liver injury as evidenced by reduced ALT and AST, and by reducing hepatic inflammatory cytokines.
Figure 3.4 Effects of PCB exposures on liver injury. (A) Plasma ALT and (B) AST levels. Hepatic mRNA levels of Tnfα (C), Ccl8 (D), Ccl3 (E), and Cxcl1 (F) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatic inflammatory response

Neutrophil and macrophage infiltration lead to liver injury, thus, CAE and immunohistochemistry (F4/80, a macrophage marker) staining were performed to evaluate neutrophil infiltration and macrophage accumulation in liver, respectively. CAE staining showed high fat diet induced neutrophil infiltration, and Aroclor 1260 exposure exacerbated this effect. PCB 126 alone or in a Aroclor 1260/PCB 126 mixture did not display the elevated neutrophil infiltration (Fig. 3.5 A&B). Likewise, more F4/80 positive brown cells were found by Aroclor 1260 exposure compared to vehicle group, while PCB 126 or Aroclor 1260/PCB 126 mixture were not elevated (Fig. 3.5 C). This result was also confirmed by measurement of gene expression of another macrophage maker, CD68. Aroclor 1260 exposure increased CD68 mRNA expression by 1.4-fold compared to vehicle group, and mixture of PCB 126 of Aroclor 1260 reversed Aroclor 1260-induced CD68 mRNA expression (Fig. 3.5 D). These results suggested Aroclor 1260 exposure, but not PCB 126 exposure, induced inflammatory cell infiltration and led to liver injury, and PCB 126 displayed anti-inflammation effects which likely accounts for the reduced plasma liver enzyme levels.
Figure 3.5 Effects of PCB exposures on hepatic inflammatory response. (A) CAE staining (40 ×). Red positive cells indicate neutrophil infiltration, (B) CAE positive number per field, (C) F4/80 immunohistochemistry staining (20 ×). Brown positive cells indicate macrophage accumulation, (D) hepatic CD68 mRNA levels. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on plasma lipids and adipokines

PCB 126 exposure led to hypolipidemia in control synthetic diet fed mice in the 2-week study. In high fat diet fed mice, PCB 126 alone or Aroclor 1260/PCB 126 exposure also decreased plasma triglycerides, but Aroclor 1260 exposure did not affect this variable (Fig. 3.6 A). Either Aroclor 1260 or PCB 126 exposure did not alter plasma total cholesterol, while co-administration of Aroclor 1260 and PCB 126 decreased total cholesterol (Fig. 3.6 B). The plasma levels of PAI-1, which is implicated in the pathogenesis of fibrosis (121), were significantly decreased by PCB 126 exposure (Fig. 3.6 C). Moreover, adipokines, including adiponectin (Fig. 3.6 C), leptin (Fig. 3.6 D) and resistin (Fig. 3.6 E) were not altered by any PCB exposure, suggesting PCB exposures may not cause adipose tissue dysfunction.
Figure 3.6 Effects of PCB exposures on plasma lipids and adipokines. Plasma levels of triglyceride (A), total cholesterol (B), PAI-1 (C), adiponectin (D), leptin (E), and resistin (F). Data are presented as mean ± SEM. n=10. p<0.05, b= PCB 126 effects, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression

Unlike the effects of PCB exposures on fatty acid β-oxidation genes expression in the 2-week study, hepatic mRNA levels of Ppara and target gene Cpt1a were decreased by either Aroclor 1260, PCB 126 or Aroclor 1260/PCB 126 mixture exposure (Fig. 3.7 A&B). Ppara mRNA expression was decreased by 9.1 %, 11.6 % and 20.1 % by Aroclor 1260, PCB 126, and Aroclor 1260/PCB 126, respectively (Fig. 3.7 A). Cpt1a mRNA expression was decreased by 5.1 %, 2.8 % and 13.6 % by Aroclor 1260, PCB 126, and Aroclor 1260/PCB 126, respectively (Fig. 3.7 B). However, the mRNA expression of Cyp4a10 had the same pattern as my 2-week study. PCB 126 increased Cyp4a10 mRNA expression 1.2-fold while the Aroclor 1260/PCB 126 mixture increased 1.5-fold (Fig. 3.7 C). These data suggested that the interaction of diet and PCB exposures affect reduction of mitochondrial fatty acid β-oxidation but increased peroxisomal fatty acid β-oxidation.

Figure 3.7 Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression. Hepatic mRNA levels of Ppara (A), Cpt1a (B), and Cyp4a10 (C) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on other genes of hepatic lipid metabolism

mRNA levels of *Cd36* were significantly increased by either PCB 126 (1.3-fold) or Aroclor 1260 (1.3-fold) exposures, and the additive induction by PCB 126 and Aroclor 1260 on *Cd36* mRNA levels were found with the Aroclor 1260/PCB 126 mixture exposure (1.5-fold) (Fig. 3.8 A). Either PCB 126 exposure slightly suppressed *Fabp1* mRNA expression, but Aroclor 1260/PCB 126 mixture exposure induced *Fabp1* mRNA expression compared to either exposure alone (Fig. 3.8 B). Both *Srebp1* (13.9 %) and *Fasn* (25.2 %) mRNA levels were decreased by PCB 126 exposure, but not by the Aroclor 1260 exposure. However, co-administration of PCB 126 and Aroclor 1260 resulted in slightly increased *Srebp1* mRNA compared to PCB 126 alone exposure, and suppressed *Fasn* mRNA expression compared to vehicle group (Fig. 3.8 C&D). Likewise, *Scd1* mRNA expression was decreased by either Aroclor 1260 (9.3 %) or PCB 126 (14.5 %) exposure, and in an additive manner by the Aroclor 1260/PCB 126 mixture (23.9 %) exposure (Fig. 3.8 E). *Pnpla3* mRNA expression was significantly upregulated by Aroclor 1260 (1.6-fold) exposure, but was suppressed by either PCB 126 (42.2 %) or Aroclor 1260/PCB 126 (37.5 %) exposure (Fig. 3.8 F). These data suggested that PCB exposures increased hepatic lipid levels due to increased lipid uptake, not by increasing *de novo* lipogenesis. Moreover, high fat diet suppressed PCB exposures-induced lipid metabolic gene expression when compared to chow diet fed mice in my 2-week study.
Figure 3.8 Effects of PCB exposures on other genes of hepatic lipid metabolism. Hepatic mRNA levels of *Cd36* (A), *Fabp1* (B), *Srebp1* (C), *Fasn* (D), *Scd1* (E), and *Pnpla3* (F) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects, c= interaction between Aroclor 1260 and PCB 126.
Effects of PCB exposures on glucose metabolism

PCB exposures are associated with diabetes in human populations. To determine whether PCB exposures affect glucose metabolism, glucose and insulin tolerance tests were performed. PCB exposures did not impair glucose tolerance and insulin sensitivity, as indicated by similar area under curves (AUCs) for all PCB exposures compared to the control group (Fig. 3.9 A&B). However, PCB 126 exposure suppressed gluconeogenic gene (Pck1) mRNA expression, and decreased fasting blood glucose levels (Fig. 3.9 C&D). Our current data are consistent with the published results by Diani-Moore S et al that activation of AhR suppressed gluconeogenic genes (Pck1) mRNA expression by TCDD via TCDD-inducible poly(ADP-ribose)-polymerase (TiPARP) (122).
Figure 3.9 Effects of PCB exposures on glucose metabolism. (A) Glucose tolerance test and area under curve (AUC); (B) insulin tolerance test and area under curve (AUC); (C) fasting blood glucose levels; hepatic mRNA levels of Pck1 (D) and G6P (E) were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, b= PCB 126 effects.
Effects of PCB exposures on hepatic fibrosis

Activated HSCs are the major source of extracellular matrix (ECM), including collagen, deposition in liver fibrosis. The balance of ECM is regulated by MMPs and TIMPs. To evaluate whether PCB exposures induced hepatic fibrosis, mRNA expression levels of fibrosis genes (e.g., TGF-β1, Acta2, Col 1α1, Col 1α2, MMPs, TIMP1, and PAI1) were measured. Although TGF-β1 mRNA expression was not affect by all PCB exposures (Fig. 3.10 A), PCB 126 alone exposure suppressed hepatic stellate cells (HSCs) activation, as indicated by decreased Acta2 (48.3 %) mRNA expression (Fig. 3.10 B). Moreover, mRNA expression of Col 1α1 (40.5 %) (Fig. 3.10 C), Col 1α2 (55.6 %) (Fig. 3.10 D), TIMP1 (64.6 %) (Fig. 3.10 E), and PAI1 (72.5 %) (Figure 3.10 F) were significantly decreased by PCB 126 exposure, but not by Aroclor 1260 exposure. The mRNA levels of ECM degradation genes, including MMP2 (Fig. 3.10 G), MMP9 (Fig. 3.10 H), and MMP14 (Fig. 3.10 I), were not significantly changed by all PCB exposures. Co-administration of Aroclor 1260 and PCB 126 did not attenuate PCB 126 exposure-induced changes in mRNA levels of these genes. Surprisingly, although PCB 126 exposure alone suppressed fibrotic genes mRNA levels, histological data showed that the collagen deposition was similar with all PCB exposures, as shown by picrosirius red staining (Fig. 3.10 J). However, mRNA changes may proceed pathological changes. These data suggested that fibrotic genes were altered by PCB exposures, but failed to cause phenotypical changes in fibrosis. Longer time and/or higher dose exposure, or the carbon tetrachloride-induced fibrosis model, should be considered to evaluate the fibrotic effects of PCB exposures.
Figure 3. Effects of PCB exposures on hepatic fibrosis. Hepatic mRNA levels of TGF-$\beta 1$ (A), Acta2 (B), Col 1a1 (C), Col 1a2 (D), TIMP1 (E), PAI1 (F), MMP2 (G), MMP9 (H), and MMP14 (I) were measured by performing RT-PCR. (J) picrosirius red staining of liver (10 ×). Data are presented as mean ± SEM. n=10. p<0.05, b= PCB 126 effects.
4. Discussion

The acute PCB exposure study (chapter 3), mice fed control synthetic diet developed hepatic steatosis and activation of AhR with PCB 126 exposure. Aroclor 1260/PCB 126 exposure also activated AhR, but failed to induce hepatic steatosis. In the current study, the interactions of diet and PCB exposures in regulation of NAFLD/NASH were investigated. I hypothesize that activation of AhR is involved in the development and progression of NAFLD/NASH after PCB exposures in high fat diet fed mice. The results demonstrated that high fat diet induced hepatic steatosis regardless of PCB exposure, Aroclor 1260 (20 mg/kg) exposure promoted progression of hepatic steatosis to steatohepatitis, while PCB 126 (20 µg/kg) exposure appeared to reverse HFD-induced hepatic fibrosis. Co-administration of PCB 126 of Aroclor 1260 abrogated Aroclor 1260 exposure-induced steatohepatitis.

Aroclor 1260 is a mixture of NDL-PCB congeners. It contains low amounts of DL PCB congeners. Aroclor 1260 exposure at this level failed to induce the AhR target gene, Cyp1a2 mRNA level in mice on either chow diet in 2-week study or with a high fat diet in the current study. These data are consistent with previous results demonstrating that Aroclor 1260 (20 mg/kg) did not activate AhR, but a high exposure of Aroclor 1260 (200 mg/kg) did (59). In the acute study (chapter 3), either PCB 126 or Aroclor 1260/PCB 126 mixture activated AhR, and co-administration of Aroclor 1260 with PCB 126 did not affect PCB 126-induced AhR activity. In the current study, AhR activity was increased by PCB 126 alone exposure, but the magnitude of AhR-dependent induction was decreased compared to the results seen in the acute study. Co-administration of Aroclor 1260 in the Aroclor 1260/PCB 126 mixture attenuated PCB 126 exposure-induced AhR activity. These
data suggested that high fat diet affects the magnitude of PCB 126 exposure-induced AhR activity. Moreover, high fat diet also impacted Aroclor 1260 exposure-induced CAR and PXR target gene expression. For example, CAR target gene Cyp2b10 mRNA was induced at least 1000-fold by either Aroclor 1260 or Aroclor 1260/PCB 126 mixture in mice fed on control chow diet as shown in chapter 3. However, less than 10-fold induction of Cyp2b10 mRNA by either Aroclor 1260 or Aroclor 1260/PCB 126 mixture was found. The magnitude of induction of Cyp2b10 mRNA by PCB 126 exposure, as shown in chapter 3, was also abolished by high fat diet.

High dose of TCDD (120) or PCB 126 (123) exposure causes a wasting syndrome. However, in the current study, neither PCB 126 nor Aroclor 1260/PCB 126 mixture exposure resulted in a wasting syndrome, as indicated by no significant body weight or epididymal fat tissue weight changes compared to the control group, although activation of AhR can be observed at lower doses of PCB 126 exposure (20 µg/kg VS. 4.9 mg/kg). Moreover, epididymal fat tissue weight was significantly increased by Aroclor 1260 exposure, possibly due to NDL-PCB 153 serving as an obesogen (124). Similar results were found in control synthetic diet fed mice in chapter 3. In low fat diet fed rats, PCB 126 exposure induced hepatic steatosis (73, 125), associated with altered hepatic micronutrients (96, 126). Our previous acute study results confirm these data that only PCB 126 exposure led to hepatic steatosis in control synthetic diet fed mice. However, in the current study, histological results showed that high fat diet induced hepatic steatosis alone, and PCB exposures did not exacerbate high fat diet-induced hepatic steatosis. These results were also confirmed by hepatic lipid levels measurement. As shown above, no PCBs exposure had effects on hepatic triglycerides or total cholesterol levels. However, PCB 126 exposure
increased hepatic free fatty acid levels compared to control group. These data suggest interactions between diet and PCB 126 exposure may affect AhR activation-induced hepatic steatosis. This may be due to the lipophilic property of PCBs, which may restrict PCBs distribution in high fat diet conditions and metabolic stress.

As mentioned in the discussion section of chapter 3, activation of CAR can be direct by ligand binding or indirect via inhibition of EGFR signaling (95). Direct activation of CAR by agonist, TCPOBOP, ameliorates metabolic syndromes, such as obesity, type 2 diabetes and NAFLD/NASH in mice under pathological conditions (85-87). However, mice administered TCPOBOP displayed hepatic lipogenesis and positive regulation of Pnpla3 gene expression. These results suggest the consequences of activation of CAR are varied under different conditions by direct ligand activation. Although Aroclor 1260 exposure induced CAR activation under either physiological condition (low fat diet) or pathological condition (high fat diet), Aroclor 1260 exposure had no effects on hepatic steatosis or glucose or insulin tolerance. However, Aroclor 1260 alone exposure promoted hepatic steatosis progression to steatohepatitis in high fat diet fed mice, which conflicts with the fact that direct activation of CAR attenuates NAFLD/NASH. These data suggest CAR is indirectly activated by Aroclor 1260 exposure. These data have been confirmed by our previous study demonstrating that Aroclor 1260 inhibits hepatic EGFR signaling (93). Other data to support this conclusion are that hepatic gluconeogenesis regulation occurs by direct CAR activation. CAR activation by agonists suppresses gluconeogenic genes (Pck1 and G6p) mRNA levels, and suppresses hepatic gluconeogenesis via degradation of PGC1alpha protein (91), or inhibition of HNF4a and FOXO1 transcriptional activity (127). In my study, Aroclor 1260 exposure did not affect hepatic gluconeogenic genes expression
and fasting blood glucose levels in either chow diet or high fat diet fed mice. In addition, PCB 126 exposure suppressed gluconeogenic genes expression, and decreased fasting blood glucose levels, consistent with previous published data (73, 79, 122).

In chapter 2, not all PCB exposures caused liver injury, as documented by similar plasma ALT and ALT levels compared to the mice on control synthetic diet fed mice, even though PCB 126 alone exposure induced mild hepatic steatosis. In the current study, Aroclor 1260 exposure induced neutrophils infiltration and macrophages accumulation in liver, and increased plasma ALT levels, which has been confirmed by our previous study (59). Interestingly, it appears that PCB 126 exposure protected against high fat diet-induced liver injury, as PCB 126 alone exposure decreased plasma AST levels, and attenuated Aroclor 1260 exposure-elevated plasma ALT levels by co-exposure of Aroclor 1260 and PCB 126. This may be due to anti-inflammatory due to AhR activation (128). This phenomenon was also found in our previous study that high dose of Aroclor 1260 (200 mg/kg) activates AhR and fails to cause liver injury (59). These results suggested that AhR activation regulates lipid metabolism and immune response through different signaling pathways.

Liver injury activates hepatic stellate cells (HSCs), and results in hepatic fibrosis by environmental pollutant exposure. TCDD exposure activates AhR, induces HSCs activation, and facilitates liver fibrosis (129, 130). However, TCDD exposure fails to exacerbate experimental liver fibrosis, although it increases necroinflammation and HSCs activation (131). This may be due to enhanced ECM turnover (132). In addition, high dose of PCB 126 exposure exacerbates MCD-induced liver fibrosis (123). In the current study, all PCB exposures did not increase collagen deposition or cause liver fibrosis, even though
Aroclor 1260 exposure increased liver injury. Surprisingly, PCB 126 exposure suppressed fibrotic gene mRNA levels, such as col 1a1, col 1a2, and TIMP1. It also decreased plasma PAI1 levels. The reasons for this are unknown, and need further investigation.

The effects of PCBs exposure on genes involved in lipid metabolism are not like the data in acute study. For example, the fatty acid β-oxidation genes mRNA levels are increased by either Aroclor 1260 or PCB 126 exposure, but inhibited by Aroclor 1260/PCB 126 exposure compared to either exposure alone. In the current study, all PCBs exposure suppressed fatty acid β-oxidation genes mRNA expression. The gene expression of fatty acid transporters mRNA was upregulated by either Aroclor 1260 or PCB 126 exposure in both diet, but the Aroclor 1260/PCB 126 mixture exposure displayed opposite results. The similar pattern also was found in Pnpla3 and fatty acid synthesis (Fasn) gene. These data suggest that unlike Aroclor 1260 or PCB 126 exposure, Aroclor 1260/PCB 126 mixture exposure exhibits different effects on genes involved in lipid metabolism with diet interaction. The DL/NDL-PCBs mixture should be used to evaluate metabolic endpoints in animal model, to allow for better prediction of the endocrine and metabolism disruption effects in humans.

In summary, high fat diet affects AhR, and CAR expression, as well as, their transcriptional activity. Aroclor 1260 exposure may indirectly activates CAR, and induces liver inflammation and injury; while PCB 126 exposure activates AhR and reduces hepatic inflammation, and attenuates Aroclor 1260 exposure-induced liver injury, and fibrosis. Moreover, both DL- and NDL-PCBs affect genes of lipid metabolism, which are associated with fatty liver disease. Mixtures of DL- and NDL-PCBs exhibit different effects on fatty liver disease compared to either alone exposure.
CHAPTER IV

COMPARISON OF CONCENTRATION-DEPENDENCE OF HUMAN AND MOUSE ARYL HYDROCARBON RECEPTOR ACTIVATION IN RESPONSE TO POLYCHLORINATED BIPHENYL EXPOSURES

1. Introduction

PCB congeners can be classified into dioxin-like (DL) and non-dioxin-like (NDL) classes. DL-PCBs have non-ortho or mono-ortho substitution and are ligands for the AhR since their planar structure allows them to fit well in the binding pocket of that receptor. The AhR plays an important role in allowing the liver to be a target for PAH metabolic action. Furthermore, other studies have shown that PCBs exposure is associated with liver disease (42), diabetes (57), and vascular disease (133), association with AhR activation.

The AhR is a transcription factor that belongs to the Per-Arnt-Sim family (67). Unliganded AhR resides in the cytoplasm of cells and upon ligand binding, translocates to the nucleus, forming a heterodimer with AHR nuclear translocator protein (ARNT). The AhR-ARNT heterodimer binds to the dioxin response element (DRE) on the 5’-flanking regions of most dioxin-responsive genes, and regulates expression of target genes, prototypically the Cyp1 family.

To estimate human risk due to AhR activation by these chemical exposure, the World Health Organization (WHO) has established toxic equivalency factors (TEFs) for AhR ligands (134). TCDD is considered the prototypical ligand for AhR and therefore, is assigned a TEF of 1. The TEFs of other chemicals are calculated based on relative effect,
potency (REP) values relative to that of TCDD. PCB 126, a non-ortho substituted PCB, which has highest AhR binding affinity of DL-PCBs, has the TEF 0.1 and is the major contributor to the total TEQ from PCBs. The TEFs of 29 AhR ligands have been calculated and have much lower TEFs than PCB 126. For example, all the TEFs of all mono-ortho substituted PCBs are 0.00003 (135).

However, TEFs are calculated for each AhR ligand in a species-specific manner, so if differences exist between the affinity for TCDD or the PCBs relative to TCDD, then there will be differences in the exposure levels required to activate the AhR. Previous Studies have compared the potency of DL-PCB congeners and/or TCDD in inducing CYP mRNA levels in the human and rodent immortalized cell lines and primary hepatocytes (136, 137). These data support the conclusion that the sensitivity of human AhR is lower than that of the rat in response to TCDD or some DL-PCB congeners exposure. The differences in primary amino acid sequence of AhR in ligand-binding pocket (138) and the different ability to recruit coactivators by AhR (139) were thought to be responsible for the different AhR sensitivity across species. Relatively, less is known about the murine AhR which was the species used in our animal studies (59, 140).

My hypothesis is that the murine AhR activation will respond to DL/NDL-PCBs mixture and DL-PCBs with lower concentration-dependence than the human AhR. To evaluate the difference of TEFs across human and mouse AhR in response to DL-PCBs exposure, human (HepG2) and mouse (Hepa1c1c7) hepatoma-derived cell line were used for AhR-dependent luciferase activity, as well as, primary human and mouse hepatocytes were used for native Cyp1a1 gene expression. Our results demonstrated that the maximal
response for human AhR in increasing gene expression was higher than that in mouse, but concentration-dependence of the human AhR is higher than that of mouse AhR.
2. Materials and Methods

Reagents

TCDD, Aroclor 1260, Aroclor 1254 (lot # 124-191) and DL-PCB congeners (PCBs 77, 81, 114, 126, 169) were purchased from AccuStandard (New Haven, CN). Lipofectamine, Opti-MEM and Wamouth’s medium, fetal bovine serum (FBS), Hank's Balanced Salt Solution (HBSS, 10X), probes for human CYP1a1 (Hs01054797_g1) and GAPDH (Hs02786624_g1), mouse Cyp1a1 (Mm00487218_m1) and GAPDH (Mm99999915_g1) for Taqman Gene Expression Assays were ordered from Thermo Fisher Scientific (Waltham, MA). Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from VWR (Radnor, PA), whereas antibiotics, 0.25 % trypsin with EDTA, Type 1 collagen, and ITS™ + Premix Universal Culture Supplement were obtained from Corning Inc. (Corning, NY). Cell culture Lysis 5x buffer and Luciferase Assay System were obtained from Promega (Madison, WI). Chlorophenol red-β-D-galactopyranoside and Collagenase D were from Sigma-Aldrich, (St. Louis, MO). RNA STAT-60 was from amsbio (Austin, TX), and QuantiTect Reverse Transcription Kit was obtained from QIAGEN (Qiagen, Valencia, CA). iTag Universal Probes Supermix was purchased form Bio-Rad (Hercules, CA). 1,2-benz[a]anthracene (BA), dimethyl sulfoxide (DMSO), ethanol, 2-propanol, chloroform and all other reagents were obtained from Sigma Aldrich.

Cell culture

The human male HepG2 and mouse Hepa1c1c7 cells were purchased from the American Type Culture Collection (Manassas, MD). Cells were cultured in DMEM complete medium supplemented with 10 % FBS and 1 % antibiotics, and incubated in 5 %
CO₂ and 95 % humidity at 37 °C. HepG2 cells and Hepa1c1c7 cells were sub-cultured every 3-4 days.

Cell transfection

The HepG2 and Hepa1c1c7 cells were plated into 24-well plates, and transfected at 40 %-50 % confluence. In brief, DMEM medium was replaced by Opti-MEM medium 30 min prior to transfection. Cells were transfected with 150 ng of a pGI₃-promoter-based reporter plasmid pXRE-SV40-Luc that has been described previously (52) and 150 ng of pCMV-β (Stratagene, CA) using lipofectamine (Thermo-Fisher) according to the manufacturer’s instructions. Following an overnight recovery period, the chemicals of interest were then added and the cells were grown for 24 hours prior to harvest. DMSO was used as a solvent control, and the final concentration was less than 0.2 %. Cells were harvested using 1x cell culture lysis buffer. Chlorophenol red β-D-galactopyranoside was used to determine β-galactosidase activity to normalize transfection efficiency. Following incubation, β-galactosidase enzyme activity was determined spectrophotometrically at 595 nm using the Bio-Tek Synergy HT multi-mode micro plate reader (Bio-Tek USA, Winooski, VT). Luciferase reporter assays were performed with a Promega Luciferase Assay System on an Orion L micro plate luminometer (Berthold Detection Systems, Pforzheim, Germany).

Primary mouse hepatocytes isolation

Livers from 10-week-old male C57BL/6 mice were used to prepare hepatocytes by digestion with collagenase D on basis of published protocol (141). Hepatocytes were resuspended in cold Waymouth’s medium, and cultured for 12 hours in type 1 collagen pre-coated 12-well plates.
Cell treatment and RT-PCR

Primary human hepatocytes were obtained from BioreclamationIVT (Baltimore, MD). Primary human hepatocytes were plated according to the supplier’s instructions in 12-well plates and cultured overnight. Chemicals of interest at indicated concentration were added to primary human and mouse hepatocytes for 24 hours. Cells were lysed and mRNA was isolated using STAT-60. RNA purity and quantity were assessed with a Nanodrop spectrometer (ND-1000, Thermo Scientific, Wilmington, DE) using ND-1000 V3.8.1 software. cDNA was synthesized using a Qiagen QuantiTect Reverse Transcription Kits. PCR reaction was performed using iTag Universal Probes Supermix, with CYP1a1 and GAPDH primers Taqman probe sets on a Bio-Rad CFX384TM Real-Time System (Hercules, CA). CYP1a1 expression level was determined using $2^{-\Delta\Delta Ct}$ methods.

Statistical analysis

Concentration-response analyses were performed on SigmaPlot 11.0 software (Systat Software Inc., San Jose, CA) using a Four Parameter Logistic Curve. Other statistical analyses performed using Graphpad Prism software (GraphPad Software Inc., La Jolla, CA). All data were normalized to uninduced control group. Data are presented as mean ± SEM. Statistical evaluation of the data was performed using one-way analysis of variance (ANOVA) followed by the Dunnett’s post hoc test to compare all groups with the control sample for multiple groups. For all statistical comparisons, p-values of less than 0.05 were considered statistically significant.
3. Results

Concentration-response curves for the luciferase assay activated by TCDD

Based on the concentration-response data, TCDD displayed an EC$_{50}$ value of 0.4 ± 0.1 nM in HepG2 cells, whereas the EC$_{50}$ value in Hepa1c1c7 cells was 0.03 ± 0.01 nM (Fig. 4.1 A&B). TCDD was much more potent, and induced luciferase activity to a significantly greater level in HepG2 cells (maximal response 83-fold compared to uninduced control group) compared to Hepa1c1c7 cells (maximal response 2.2-fold compared to uninduced control group).

A                                                              B

\[
\begin{align*}
EC_{50} &= 0.4 \pm 0.1 \text{ nM} \\
EC_{50} &= 0.03 \pm 0.01 \text{ nM}
\end{align*}
\]

Figure 4.1 Concentration-response curves for the luciferase assay activated by TCDD. AhR-dependent luciferase activity in HepG 2 cells (A) and Hepa1c1c7 cells (B) treated with various of concentrations of TCDD. Data are presented as mean ± SEM.
Concentration-response curves for the luciferase assay and Cyp1a1 expression activated by non-ortho PCB 126

Because PCB 126 is thought to be the congener with the greatest contribution to the overall TEQ provided by PCBs, we examined the concentration dependence in both human HepG2 cells and mouse Hep1c1c7 cells. Our results show that PCB 126 had an EC$_{50}$ value of 250 ± 150 nM in HepG2 cells, while EC$_{50}$ value in Hepa1c1c7 cells was 4.7 ± 3.2 nM (Fig. 4.2 A&B). PCB 126 induced luciferase activity to a significantly greater level in HepG2 cells (maximal response 31.6-fold compared to uninduced control group) compared to Hepa1c1c7 cells (maximal response 5.9-fold compared to uninduced control group).

Using primary human and mouse hepatocytes, real-time PCR was used to measure CYPIA1 and Cyp1a1 mRNA levels, respectively, when treated with PCB 126. PCB 126 induced expression of CYPIA1 with an EC$_{50}$ value of 195 ± 35 nM in primary human hepatocytes. The EC$_{50}$ value for Cyp1a1 in primary mouse hepatocytes was 12.3 ± 7.9 nM (Fig. 4.2 C&D). The maximal fold Cyp1a1 mRNA induction did not display a significant difference between primary human (45.1-fold compared to uninduced control group) and mouse hepatocytes (53.3-fold compared to uninduced control group).
Figure 4.2 Concentration-response curves for the luciferase assay and Cyp1a1 expression activated by non-ortho PCB 126. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with various of indicated concentration of PCB 126. AhR target gene Cyp1a1 induction in primary human (C) and mouse (D) hepatocytes after the same treatment with the indicated concentration of PCB 126. Data are presented as mean ± SEM.
Concentration-response curves for the luciferase assay activated by non-ortho PCB 169

PCB 169 was tested using the reporter gene assay, in which HepG2 and Hepa1c1c7 cells were treated with various concentrations of PCB 169 up to 10 µM (Fig. 4.3 A&B). Based on the concentration-response data, the EC$_{50}$ value was 25.7 ± 4.6 nM in Hepa1c1c7 cells, whereas the EC$_{50}$ value in HepG2 cells could not be determined, because of the failure to reach the maximum effect.

Figure 4.3 Concentration-response curves for the luciferase assay activated by non-ortho PCB 169. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with the indicated concentration of PCB 169. Data are presented as mean ± SEM.
Concentration-response curves for the luciferase assay activated by non-ortho PCB 81

Unlike others dioxin-like PCB congeners, PCB 81 had approximately 5-fold higher EC$_{50}$ value in Hepa1c1c7 cells (32.0 ± 17.7 nM), compared to the EC$_{50}$ value in HepG2 cells (6.8 ± 2.7 nM) (Fig. 4.4 A&B).

EC$_{50}$ = 6.8 ± 2.7 nM  
EC$_{50}$ = 32.0 ± 17.7 nM

Figure 4.4 Concentration-response curves for the luciferase assay activated by non-ortho PCB 81. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with various of concentrations of PCB 81. Data are presented as mean ± SEM.
Concentration-response curves for the luciferase assay activated by mono-ortho PCB 114

PCB 114 induced luciferase activity to a significantly greater level in HepG2 cells, compared to Hepa1c1c7 cells. Based on the concentration-response data, the EC$_{50}$ value of PCB 114 was 796 ± 661 nM in Hepa1c1c7 cells, whereas the EC$_{50}$ value in HepG2 cells was not attained because of the inability to reach the maximal effects, like PCB 169 (Fig. 4.5 A&B).

![Concentration-response curves for the luciferase assay activated by mono-ortho PCB 114. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with the indicated concentration of PCB 114. Data are presented as mean ± SEM.](image)

**Figure 4.5** Concentration-response curves for the luciferase assay activated by mono-ortho PCB 114. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with the indicated concentration of PCB 114. Data are presented as mean ± SEM.
Concentration-response curves for the luciferase assay activated by non-ortho PCB 77

PCB 77 induced luciferase activity to a higher level in HepG2 cells, compared to Hepa1c1c7 cells. The EC$_{50}$ value for PCB 77 was 108 ± 39 nM in Hepa1c1c7 cells, whereas EC$_{50}$ value in HepG2 cells was again not attained because of failure to reach the maximal effect (Fig. 4.6 A&B).

![Concentration-response curves for the luciferase assay activated by non-ortho PCB 77](image)

EC$_{50}$ = None

EC$_{50}$ = 108.2 ± 38.8 nM

Figure 4.6 Concentration-response curves for the luciferase assay activated by non-ortho PCB 77. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with various of concentrations of PCB 77. Data are presented as mean ± SEM.
DL/NDL-PCBs mixture activates mouse AhR

HepG2 and Hepa1c1c7 cells were transfected with AhR-dependent (pXRE-SV40-Luc) reporter plasmid, then treated with Aroclor 1260 (10 µg/ml), Aroclor 1254 (10 µg/ml), PCB 126 (3.26 µg/ml; 10 µM), or the DL/NDL-PCBs mixture (Aroclor 1260 (10 µg/ml) plus 0.1 % PCB 126 (10 ng/ml; 0.0306 µM), Aroclor 1260/PCB 126), and positive control 1,2-benz[a]anthracene (BA, 2.28 µg/ml; or 50 µM). These concentrations have been shown not to cause cellular toxicity (52). As anticipated, BA increased luciferase activity 67.4-fold in HepG2 cells and 5.1-fold in Hepa1c1c7 cells when compared with vehicle group. Likewise, PCB 126 induced a 42.2-fold increase in luciferase activity in HepG2 cells and a 3.7-fold increase in Hepa1c1c7 cell lines. Neither Aroclor 1260 nor Aroclor 1254 induced luciferase activity in either HepG2 or Hepa1c1c7. In contrast, the mixture of Aroclor 1260/PCB 126 induced luciferase in only the Hepa1c1c7 cell line by 3.0-fold. It is important to note that the concentration of PCB 126 (0.0306 µM) is much lower in the DL/NDL-PCBs mixture than the 10 µM used as a control (Fig. 4.7 A&B).

The expression of the prototypical AhR target gene CYP1A1 was measured using RT-PCR in primary human and mouse hepatocytes treated with chemicals of interest. As anticipated, BA increased the expression of CYP1A1 message 616-fold in human primary hepatocytes and 398-fold in murine primary hepatocytes. Likewise, addition of 10 µM PCB 126 induced CYP1A1 message 225-fold in human hepatocytes and 187-fold in murine hepatocytes. Neither Aroclor 1260 nor Aroclor 1254 induced mRNA expression of either CYP1A1 or Cyp1a1 in human and murine hepatocytes, respectively. Consistent with the luciferase assay results, the DL/NDL-PCBs mixture group showed no significant elevation of CYP1A1 mRNA expression in primary human hepatocytes, but exhibited markedly
increased expression of *Cyp1a1* message in primary mouse hepatocytes (112-fold) (Fig. 4.7 C&D). These data demonstrated that regardless of using isolated hepatocytes or immortalized cell lines, the trends are consistently similar among these treatments. The results suggested that the maximal response of human AhR was higher than that of mouse AhR, but ligands were more potent for the murine AhR.
Figure 4.7 DL/NDL-PCBs mixture activates mouse AhR. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with Aroclor 1260 (10 µg/ml), Aroclor 1254 (10 µg/ml), PCB 126 (10 µM), DL/NDL-PCBs mixture (Aroclor 1260 (10 µg/ml) plus 0.1% PCB 126 (10 ng/ml; 0.0306 µM), Aroclor 1260/PCB 126), and positive control 1,2-benz[a]anthracene (BA, 10 µM). AhR target gene CYP1a1 induction in primary human (C) and mouse (D) hepatocytes after the same treatment with luciferase activity assay. Data are presented as mean ± SEM. **p<0.01, and ***p<0.001 VS vehicle.
4. Discussion

The main objective of the current study was to test the hypothesis that DL-PCBs exhibited higher concentration-dependence for the mouse AhR activation than for human AhR. Neither, Aroclor 1260 nor 1254 activated AhR or induced AhR-dependent gene expression in either cell line, suggesting that the major PCB congeners in this mixture are not effective AhR ligands. This was expected for Aroclor 1260 as it contains low levels of DL-PCBs and requires exposures over 20 mg/kg to induce Cyp1a2 in murine whole animal models (59). In contrast, we expected Aroclor 1254 would activate AhR as it contains more penta- and less-highly chlorinated PCBs than the hexa- and hepta-substituted PCBs that predominate in Aroclor 1260; therefore, Aroclor 1254 should have higher levels of DL-PCBs. The amounts of DL-PCBs in Aroclor 1254 varies considerably (142) by lot and we used lot 124-191 rather than lots like lot 6024 which contains approximately 10-fold higher DL-PCBs. Thus, it is possible that induction may have been observed with Aroclor 1254, had we used another lot.

We designed a DL/NDL-PCBs mixture containing more dioxin-like congeners (Aroclor 1260 plus 0.1% PCB 126) to approximate the human PCB exposure profiles seen in the general U.S. population (98). We found that this fortified DL/NDL-PCBs mixture activated AhR in murine cells, but failed to induce human AhR in transfection experiments in immortalized cell lines and in primary human or mouse hepatocytes. This suggests that the affinity values for DL-PCBs, i.e., EC$_{50}$ values, are considerably lower in murine systems than in human cells (Table 4.1).

As anticipated, PCB 126, the most potent DL-PCB ligand for the AhR, increased AhR luciferase activity in immortal cells or increased Cyp1a1 mRNA levels in primary
hepatocytes regardless of species at 10 µM. The fold induction with either BA or PCB 126 was significantly lower in the Hepa1c1c7 cell line than in the HepG2 cell line, but similar in the primary hepatocytes. This most likely is a cell line-dependent effect, possibly as a result of a rapid decrease in AhR protein after translocation to the nucleus in Hepa1c1c7 cells (143). The more relevant fold-inductions from primary mouse and human hepatocytes were similar. This likely reflects similarities in the activation domains between the two receptors and similarities in the number and sequence of the AhR responsive elements of either CYP1A1 or Cyp1a1.

In this study, the EC$_{50}$ value for TCDD in both cell lines was not similar, 0.4 ± 0.1 nM in HepG2 cells and 0.03 ± 0.01 nM in Hepa1c1c7 cells. This was approximately 4-fold higher than previously published studies (144-146).

The EC$_{50}$-based potencies for DL-PCBs in HepG2 cells in rank order was TCDD > PCB 81 > PCB 126, consistent with previous studies (136) that used CYP 1A1 activity assays to determine EC$_{50}$-based potencies in HepG2 cells (Table 4.2). The EC$_{50}$-based relative potency values (REPs) were calculated (Table 4.2). In HepG2 cells, the REPs of PCB 126 and PCB 81 were 0.002 and 0.06, respectively within species, consistent with previous studies (136). The EC$_{50}$ values of various DL-PCB congeners were lower in Hepa1c1c7 cells except for PCB 81 that displayed a lower EC$_{50}$ in HepG2 cells than PCB 126, but a higher EC$_{50}$ in Hepa1c1c7 cells. The rank order of EC$_{50}$-based potencies in mouse Hepa1c1c7 cells was TCDD > PCB 126 > PCB 169 > PCB 81 > PCB 77 > PCB 114 (145). This is nearly identical to results observed with the rat H4IIE cell line (136). In our study with Hepa1c1c7 cells, the REPs in table 4.2 for PCB 126 was 0.006, PCB 81 was
0.0009, PCB 77 was 0.0003, PCB 114 was 0.00004, and PCB 169 was 0.001 which are much lower than the rat REPs.

In contrast to the mouse and human REPs, the rat REPs are reported to be much higher for DL-PCBs in rat H4IIE cells and rat primary hepatocytes. The WHO 2005 TEF values are based on a combination of rodent and human REPs. The species most commonly used in PCB studies is the rat, so the WHO 2005 TEF values likely reflect this and may vary considerably from that observed in humans. With TEF, the toxicity of a mixture of dioxins or dioxin-like chemicals could be defined by the toxic equivalency (TEQ); it can be calculated by the sum of the concentrations of individual chemicals (Ci) multiplied by their relative toxicity (TEF). Thus, the WHO 2005 TEF for PCB 126 is 0.1, far higher than our human REP of 0.002. In contrast to the PCBs, published consensus toxicity factors for polychlorinated dibenzo-p-dioxins and dibenzofurans (145) are much more closely aligned to WHO 2005 TEFs, suggesting that the human TEQ may represent a result dominated by these compounds with PCBs having only a small effect. Of relevance to humans, the PCB load we receive from food consumption (147) in which PCBs make up approximately 30% of the TEQ using WHO 2005 TEFs. If this were adjusted using our REPs and that of others (145), it would only be a few percent at best.

Likewise, in our previous animal studies (59), Aroclor 1260 made steatohepatitis worse in animals fed a high fat diet at exposures that did not appear to significantly induce Cyp1a2 gene expression. In mice, the different AhR ligands activate different subsets of genes leading to the concept of selective modulation of the AhR (148) and it is unclear whether the human AhR behaves in a similar manner. As the human AhR has higher affinity for either dietary indole metabolites or tryptophan metabolites than the mouse AhR.
(149), it may be important to determine whether PCBs act like the dietary and endogenous ligands or like dioxin-like compounds.

In summary, the results demonstrated the sensitivity of mouse AhR, as indicated by lower EC50 value, is higher than human AhR in response to dioxin exposure and even more so with DL-PCBs like PCB 126. In addition, the DL/NDL-PCBs mixture designed to approximate human exposures and bioaccumulation patterns activated the mouse AhR, but not the human AhR. These results suggest that the animal exposure models in chapter 2 and 3 should be referred to increase human relevance. This could be accomplished by using humanized AhR mice.
### Table 4.1 AhR EC$_{50}$ values in human and mouse

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Type $^a$</th>
<th>HepG2 (nM)</th>
<th>Hepa1c1c7 (nM)</th>
<th>Primary human hepatocytes (nM)</th>
<th>Primary mouse hepatocytes (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCDD</td>
<td>n</td>
<td>0.4±0.1</td>
<td>0.03±0.01</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>PCB 77</td>
<td>n</td>
<td>n.d. $^b$</td>
<td>108.2 ±38.8</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>PCB 81</td>
<td>n</td>
<td>6.8±2.7</td>
<td>32.0±17.7</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>PCB 126</td>
<td>n</td>
<td>250±150</td>
<td>4.7±3.2</td>
<td>194.5±35.2</td>
<td>12.3±7.9</td>
</tr>
<tr>
<td>PCB 169</td>
<td>n</td>
<td>n.d.</td>
<td>25.7 ±4.6</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>PCB 114</td>
<td>m</td>
<td>n.d.</td>
<td>796.5 ±660.5</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

Note. EC$_{50}$ values calculated 24 hours after treatment with TCDD and DL-PCB congeners.

$^a$ n means non-ortho; m means mono-ortho.

$^b$ n.d. means not/no detectable.

### Table 4.2 Relative Effect Potency Values (REPs)

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Type $^a$</th>
<th>HepG2</th>
<th>Hepa1c1c7</th>
<th>WHO-TEF $^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCDD</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>PCB 77</td>
<td>n</td>
<td>n.d. $^b$</td>
<td>0.0003</td>
<td>0.0001</td>
</tr>
<tr>
<td>PCB 81</td>
<td>n</td>
<td>0.06</td>
<td>0.0009</td>
<td>0.0003</td>
</tr>
<tr>
<td>PCB 126</td>
<td>n</td>
<td>0.002</td>
<td>0.006</td>
<td>0.1</td>
</tr>
<tr>
<td>PCB 169</td>
<td>n</td>
<td>n.d.</td>
<td>0.001</td>
<td>0.03</td>
</tr>
<tr>
<td>PCB 114</td>
<td>m</td>
<td>n.d.</td>
<td>0.00004</td>
<td>0.00003</td>
</tr>
</tbody>
</table>

$^a$ n means non-ortho; m means mono-ortho.

$^b$ n.d. means not/no detectable.

$^c$ Van den Berg et al. (2006)
CHAPTER V
CONCLUSIONS

1. Overall goals and specific aims

The goals of the current dissertation are to investigate and compare low doses of DL-PCB congener (PCB 126, 20 µg/kg), NDL-PCBs mixture (Aroclor 1260, 20 mg/kg), and DL/NDL-PCBs mixture exposure (mixture of Aroclor 1260 and PCB 126)-induced NAFLD/NASH and metabolic dysfunction, as well as, to investigate the role of AhR in PCBs exposure-induced NAFLD/NASH. The outcomes of these studies have provided us a better understanding of different PCB exposures-induced NAFLD/NASH. The specific aims are shown as follows:

Specific Aim 1 addressed whether DL-PCBs, NDL-PCBs, and DL/NDL-PCBs act differently on fatty liver disease.

1a. Determined the activation of AhR and liver injury stimulated by DL-PCB and DL/NDL-PCBs mixture in a two-week treatment in mice on control synthetic diet.

1b. Determined the effects of DL-PCB and DL/NDL-PCBs mixture in NAFLA/NASH in a twelve-week treatment in mice on high fat diet via interaction with AhR.

Specific Aim 2 addressed whether human and murine AhR display the same concentration-dependence for ligand activation in response to PCBs.

2a. Determined the half maximal effective concentration (EC$_{50}$) for DL-PCB congeners in HepG2 cells and Hepa1c1c7 cells transfected with a XRE-luciferase reporter.
2b. Determined the concentration-dependence of AhR activation in murine and human primary hepatocytes treated with DL-PCBs and DL/NDL-PCBs mixture.

2. Major findings of current dissertation

In my dissertation, specific aim 1 addressed whether DL-PCBs, NDL-PCBs, and DL/NDL-PCBs act differently on fatty liver disease. A new human relevant PCB exposures animal model was established to evaluate different outcomes of DL-, NDL-, and DL/NDL-PCBs mixture exposure in NAFLD/NASH. In the control synthetic diet acute PCB exposures model, DL-PCB 126 exposure induced AhR activation, and caused mild hepatic steatosis (lean NAFLD), and DL/NDL-PCBs mixture exposure targeted pancreas, and caused pancreatic dysfunction, a condition termed PCB exposure-induced pancreatopathy.

In high fat diet chronic PCB exposures model, Aroclor 1260 promoted steatosis progression to steatohepatitis (obese NASH), while DL-PCB 126 attenuated Aroclor 1260 exposure-induced steatohepatitis. Novel mechanisms of PCB exposures-induced toxicity related to NAFLD/NASH, such as liver-pancreas axis, β cell identity, hepatokines, and Pnpla3 were observed in the animal models. Please refer to supplemental table 1 &2 for detailed information. Specific aim 2 addressed whether human and murine AhR display the same concentration-dependence for ligand activation in response to PCBs. The results demonstrated that the concentration-dependence of mouse AhR activation by DL-PCBs is much lower than human AhR, suggesting species difference for AhR activation, and the same difference was also found in REPs in response to PCBs exposure. Difference between human and mouse AhR relative ligand affinity indicated that humanized AhR mouse model should be used relevant to specific aim 1to better evaluate risks of PCB exposures in humans.
3. Strengths and limitations of this dissertation

Strengths

There are several strengths in this dissertation. First strength is environmentally relevant DL/NDL-PCBs mixture exposure induces AhR activation in vivo, and the extent of AhR activation by this PCBs mixture is similar to low dose of PCB 126 exposure, and the histological changes and molecule level of lipid metabolism gene expression are different with this PCBs mixture exposure compared to either exposure alone. This result may be due to the interaction of transcription factors, as well as diet effects. In addition, DL/NDL-PCBs mixture also induces pancreatic structure changes and dysfunction, termed PCBs exposure-induced pancreatopathy. These data suggest to us that DL/NDL-PCBs mixture should be used when we evaluate a PCB exposures-induced metabolic disease, providing data that more closely reflect in human. Another strength is that our AhR relative ligand affinity assay demonstrates activation of mouse AhR is much more sensitive to dose than human AhR by dioxin-like PCB congeners exposure. Moreover, DL/NDL-PCBs mixture at the concentration tested only activates mouse AhR, not human AhR. These data suggest a species difference between human and mouse that should be considered when evaluating the risk of PCBs mixture exposure that contain dioxin-like PCB congeners, and the data generated could provide us better understanding of PCB exposure-induced disease in humans.

Limitations

Although the phenotypic changes are significantly different by specific PCB exposures, we will not be able to provide a molecular mechanism that is responsible for these changes. However, our results suggest nuclear receptor, AhR, hepatokines, and Pnpla3 could be
influenced. A proteomic and/or RNA sequencing analysis could be done to identify different proteins and/or genes that might provide us an insight for these phenotypical changes. PCB exposures-induced AhR, PXR, and CAR activation, were associated with phenotypic changes; however, the exact role of these receptors’ activation in PCB exposures-induced liver disease is unclear. In addition, potential sex differences were also not considered in this dissertation, as PCBs interact with estrogen receptor (51) and AhR activation causes loss of liver specific and sexually dimorphic gene expression (150). AhR is also expressed in gut, and may impact liver disease through gut-liver axis. Thus, the hepatocyte AhR-specific knockout mice, and/or combination with CAR/PXR double knockout mice might be used to better understand the potential mechanisms. (151). Moreover, PCBs exposure disrupts intestinal integrity (152) and induces dysbiosis of the gut microbiota (153, 154). Therefore, investigation of gut microbiota would be performed with the varying PCB exposures. These data may distinguish the causative of various of changes by different PCB exposures. Lastly, the humanized AhR mouse should be used to better evaluate risk of PCBs exposure, due to the different AhR relative ligand affinity across species.

4. Summary

Taken together, both PCB 126 or the DL/NDL-PCBs mixture activated AhR, while Aroclor 1260 exposure activated CAR and PXR in either control synthetic diet or high fat diet. However, high fat diet abrogated PCB exposures-induced xenobiotic receptor activation. The effects of PCB exposures on liver lipid homeostasis were summarized in Figure 5.1. PCB 126 exposure induced mild hepatic steatosis in control synthetic diet model (lean NAFLD), while Aroclor 1260 exposure promoted steatosis progression to
steatohepatitis (obese NASH) in high fat diet model. Regardless of the diet effects, PCB exposures increased lipid influx to liver, and decreased *de novo* lipogenesis. Moreover, PCB 126 exposure decreased fasting blood glucose via inhibition of hepatic gluconeogenic gene mRNA expression, and induced hypolipidemia. For fatty acid β-oxidation, PCB exposures exhibited different effects on mRNA expression for these genes. Other potential mechanisms include hepatokines, Pnpla3 mRNA transcription. The DL/NDL-PCBs mixture caused pancreatopathy which warrant future study. Difference in ligand concentration-dependence of AhR activation between human and mouse was observed by DL-PCB congeners exposure, and DL/NDL-PCBs mixture exposure activated mouse AhR. These results suggested that utilizing an environmentally relevant mixture of PCBs containing both DL- and NDL-PCB congeners is important in the study of endocrine and metabolic disruption because the combined effects may be different than the effects of either type of PCB alone. Due to species difference in PCB-ligand activation of AhR, humanized AhR mice should be used in the future study.
Figure 5.1 PCB exposures affected homeostasis of liver lipid metabolism.
Supplemental Table 1 Effects of PCB exposures on liver, pancreas and blood in mice fed on control synthetic diet for 2 weeks.

<table>
<thead>
<tr>
<th>Targets</th>
<th>Effects</th>
<th>Aroclor 1260</th>
<th>PCB 126</th>
<th>Aroclor 1260/PCB 126</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>Cytochrome P450s</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Cyp1a2 induction</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Cyp2b10 induction</td>
<td>↑ (+/+</td>
<td>↑ (-/-)</td>
<td>↑ (+/-) *</td>
</tr>
<tr>
<td></td>
<td>Cyp3a11 induction</td>
<td>↑</td>
<td>↔</td>
<td>↔ *</td>
</tr>
<tr>
<td></td>
<td>Steatosis</td>
<td>↔</td>
<td>↑</td>
<td>↔ *</td>
</tr>
<tr>
<td></td>
<td>Injury</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Lipid uptake gene mRNA levels</td>
<td>↑</td>
<td>↑</td>
<td>↔ *</td>
</tr>
<tr>
<td></td>
<td>Fatty acid β-oxidation gene mRNA levels</td>
<td>↔</td>
<td>↑</td>
<td>↔ *</td>
</tr>
<tr>
<td></td>
<td>Fatty acid synthesis gene mRNA levels</td>
<td>↓</td>
<td>↓</td>
<td>↔ *</td>
</tr>
<tr>
<td></td>
<td>Hepatokine gene mRNA levels</td>
<td>FGF21</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IGF1</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Betatrophin</td>
<td>↑</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Gluconeogenesis gene mRNA levels</td>
<td>↔</td>
<td>↓</td>
<td>↔ *</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Atrophy</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Acinar cell steatosis</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Fibrosis</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Insulin1 gene mRNA levels</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Pancreatic polypeptide gene mRNA levels</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Islet identity gene mRNA levels</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Blood</td>
<td>Fasting glucose</td>
<td>↔</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Lipid</td>
<td>↔</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Insulin</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Systemic inflammation</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
</tbody>
</table>

Notes:
1. ↔ indicates no change; ↑ indicates increase; ↓ indicates decrease versus vehicle control;
2. + indicates numerical high; - indicates numerical low;
3. * indicates interaction between Aroclor 1260 and PCB 126.
Supplemental Table 2 Effects of PCB exposures on liver and blood in mice fed on high fat diet for 12 weeks.

<table>
<thead>
<tr>
<th>Targets</th>
<th>Effects</th>
<th>Aroclor 1260</th>
<th>PCB 126</th>
<th>Aroclor 1260/PCB 126</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>Cytochrome P450s</td>
<td>Cyp1a2 induction</td>
<td>↔</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyp2b10 induction</td>
<td>↑ (+)</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Steatosis</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Injury</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Inflammation</td>
<td>↑</td>
<td>↔</td>
<td>↔*</td>
</tr>
<tr>
<td></td>
<td>Lipid uptake gene mRNA levels</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Fatty acid β-oxidation gene mRNA levels</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Fatty acid synthesis gene mRNA levels</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Fibrosis</td>
<td>Fibrotic gene mRNA levels</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenotype</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Gluconeogenesis gene mRNA levels</td>
<td>↔</td>
<td>↓</td>
<td>↔</td>
</tr>
<tr>
<td>Blood</td>
<td>Fasting glucose</td>
<td>↔</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Lipid (triglyceride)</td>
<td>↔</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Adipokines</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td></td>
<td>Tolerance test</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
</tbody>
</table>

Notes:
1. ↔ indicates no change; ↑ indicates increase; ↓ indicates decrease versus vehicle control;
2. + indicates numerical high; - indicates numerical low;
3. * indicates interaction between Aroclor 1260 and PCB 126.
REFERENCES


64. Yu M-L, Guo YL, Hsu C-C, Rogan WJ. Increased mortality from chronic liver disease and cirrhosis 13 years after the Taiwan “yucheng” (“oil disease”) incident. American Journal of Industrial Medicine 1997;31:172-175.


120. Brewster DW, Matsumura F. Reduction of adipose tissue lipoprotein lipase activity as a result of in vivo administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin to the guinea pig. Biochem Pharmacol 1988;37:2247-2253.


# ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AhR</td>
<td>Aryl hydrocarbon receptor</td>
</tr>
<tr>
<td>ARNT</td>
<td>AhR nuclear translocator</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>BA</td>
<td>1,2-benz[a]anthracene</td>
</tr>
<tr>
<td>CAR</td>
<td>Constitutive androstane receptor</td>
</tr>
<tr>
<td>CCL8</td>
<td>Chemokine (C-C motif) ligand 8</td>
</tr>
<tr>
<td>Cpt1α</td>
<td>Carnitine palmitoyl transferase 1A</td>
</tr>
<tr>
<td>CXCL1</td>
<td>Chemokine (C-X-C motif) ligand 1</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochromes P450</td>
</tr>
<tr>
<td>CITCO</td>
<td>6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehydeO-(3,4dichlorobenzyl)oxime</td>
</tr>
<tr>
<td>DL</td>
<td>Dioxin like</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DRE</td>
<td>Dioxin-responsive element</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>EDCs/MDCs</td>
<td>Endocrine and metabolism disrupting chemicals</td>
</tr>
<tr>
<td>FABP1</td>
<td>Fatty acid-binding protein 1</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>FASN</td>
<td>Fatty acid synthase</td>
</tr>
<tr>
<td>FGF21</td>
<td>Fibroblast growth factor 21</td>
</tr>
<tr>
<td>FoxO1</td>
<td>Forkhead box protein O1</td>
</tr>
<tr>
<td>G6P</td>
<td>Glucose 6-phosphate</td>
</tr>
<tr>
<td>GTT</td>
<td>Glucose tolerance test</td>
</tr>
<tr>
<td>HCC</td>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>HDL</td>
<td>High-density lipoprotein</td>
</tr>
<tr>
<td>HNF4α</td>
<td>Hepatocyte nuclear factor 4 alpha</td>
</tr>
<tr>
<td>HFD</td>
<td>High fat diet</td>
</tr>
<tr>
<td>IGF1</td>
<td>Insulin-like growth factor 1</td>
</tr>
<tr>
<td>IL6</td>
<td>Interleukin 6</td>
</tr>
<tr>
<td>ITT</td>
<td>Insulin tolerance test</td>
</tr>
<tr>
<td>LDL</td>
<td>Low-density lipoprotein</td>
</tr>
<tr>
<td>MCP1</td>
<td>Monocyte chemoattractant protein 1</td>
</tr>
<tr>
<td>MCD</td>
<td>Methionine choline-deficient</td>
</tr>
<tr>
<td>MMPs</td>
<td>Matrix metalloproteases</td>
</tr>
<tr>
<td>NAFLD/NASH</td>
<td>Nonalcoholic fatty liver disease /steatohepatitis</td>
</tr>
<tr>
<td>NDL</td>
<td>Non-dioxin like</td>
</tr>
<tr>
<td>nHDLc</td>
<td>non-HDL cholesterol</td>
</tr>
<tr>
<td>NR</td>
<td>Nuclear receptor</td>
</tr>
<tr>
<td>PAI1</td>
<td>Plasminogen activator inhibitor-1</td>
</tr>
<tr>
<td>PCB</td>
<td>Polychlorinated biphenyl</td>
</tr>
<tr>
<td>Pck1</td>
<td>Phosphoenolpyruvate carboxy kinase</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>PGC1α</td>
<td>Peroxisome proliferator-activated receptor gamma coactivator 1-alpha</td>
</tr>
<tr>
<td>PNPLA3</td>
<td>Patatin-like phospholipase domain-containing protein 3</td>
</tr>
<tr>
<td>PPARα</td>
<td>Peroxisome proliferator-activated receptor alpha</td>
</tr>
<tr>
<td>PXR</td>
<td>Pregnane X receptor</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse transcription-polymerase chain reaction</td>
</tr>
<tr>
<td>SCD1</td>
<td>Stearoyl coenzyme A desaturase1</td>
</tr>
<tr>
<td>TAFLD/TASH</td>
<td>Toxicant associated fatty liver disease/steatohepatitis</td>
</tr>
<tr>
<td>TCDD</td>
<td>2,3,7,8-tetrachlorodibenzo-p-dioxin</td>
</tr>
<tr>
<td>TCPOBOP</td>
<td>1,4-bis[2-(3,5-dichloropyridyloxy)]benzene</td>
</tr>
<tr>
<td>TIMPs</td>
<td>Tissue inhibitors of metalloproteinases</td>
</tr>
<tr>
<td>TNFα</td>
<td>Tumor necrosis factor-alpha</td>
</tr>
<tr>
<td>VLDL</td>
<td>Very low-density lipoprotein</td>
</tr>
</tbody>
</table>
CURRICULUM VITAE

Hongxue Shi
University of Louisville School of Medicine
Department of Pharmacology and Toxicology
Louisville, KY 40292

Email: s0hong10@louisville.edu
Phone: 502-296-5219

EDUCATION

2014-Present  University of Louisville
  •  Ph.D. candidate, Pharmacology and Toxicology

2010-2013  Wenzhou Medical University
  •  M.S., Pharmacology

2006-2010  Huaiyin Institute of Technology
  •  B.S., Pharmaceutical Engineering

WORK EXPERIENCE

2014- Present  Graduate Research Assistant, Program in Pharmacology & Toxicology, Graduate School, University of Louisville
2013-2014  Lab Manager, School of Pharmacology, Wenzhou Medical University

ABSTRACTS

1.  *Hongxue Shi*, Josiah E. Hardesty, Jian Jin, Heather B. Clair, Cameron K. Falkner, Russell A. Prough, Matthew C. Cave. Chronic PCB Exposure Disrupts Hepatic Xenobiotic and Intermediary Metabolism and Increases Hepatic Inflammation/Injury. 2018; Society of Toxicology Poster

3. *Josiah E. Hardesty, Bradley J. Vivace, Hongxue Shi, Jian Jin, Cameron K. Falkner, Russell A. Prough, Matthew C. Cave. Epideomal growth factor receptor inhibition is a conserved mechanism for environmental pollutants in nonalcoholic fatty liver disease. 2017; AASLD.


**PROFESSIONAL MEMBERSHIPS**

2016-Present  Society of Toxicology (SOT)
2016-Present  American Association for the Advancement of Science (AAAS)
129


